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2’ -5’ –oligoadenylate synthetase 1 (OAS1) is an antiviral enzyme that in the 
presence of double-stranded RNA structures, such as viral genomes or single-stranded 
RNA transcripts with significant double-stranded character, converts ATP to a series of 2’ 
-5’ –oligoadenylates (2-5A). 2-5A promotes dimerization of latent ribonuclease (RNaseL) 
to form catalytically active RNaseL, a candidate hereditary prostate cancer (PCa) gene. 
RNaseL is anti-proliferative and promotes senescence and apoptosis in PCa cells. 
Genotyping analysis was completed on over 600 genomic DNA samples from African-
American and Caucasian, normal and PCa subjects. Genotyping was performed to screen 
the following SNPs in the last exon of OAS1 (rs10774671, rs1131476, rs1051042 and 






The rs10774671 GG and AA genotypes generate isoform 1 (p46) and isoform 3 
(p48), respectively and were distributed equally in the healthy population. However, in 
cases, the AA genotype (p46) was significantly associated with PCa risk (OR: 1.80, P-
value: < 0.0001). The genotypic frequencies of rs1131476, rs1051042 and rs2660 
demonstrated significant LD but showed no association to PCa risk. We also identified 
protective (AACA, OR =0.06612, P < 0.001) and risk (GACA, OR= 2.31, p <0.0001) 
haplotypes from the combined analysis of rs10774671, rs1131476, rs1051042 and rs2660 
with PCa.  
Additionally, we utilized two genome-wide association studies analyzing OAS1 
and variants found on chromosome 12 to determine their relationship with PCa 
susceptibility for meta-analysis: This was done to elucidate the role of OAS1 SNPs and 
chromosome 12 variants in a larger population cohort with PCa susceptibility for a greater 
understanding of gene to gene interactions. The genome wide association studies used 
were, the Geneva Multiethnic Genome-wide Scan of Prostate Cancer (MEC), containing 
2,841 African-American samples (1,343 cases and 1,498 controls) and 1,660 
Japanese/Latino samples (834 cases and 826 controls), as well as Cancer Genetic Markers 
of Susceptibility (CGEMS) Prostate Cancer-Primary Scan (Stage 1) - PLCO which 
contains 2,841 samples of European ancestry (1,172 cases and 1,157 controls). We used 
PLINK, a whole genome association analysis toolset, to extract data on SNPs in association 
with PCa.  
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Interferon-stimulated genes (ISG’s) are of significant interest in understanding 
prostate cancer (PCa) etiology.1 2’-5’ Oligoadenylate synthetase 1 (OAS1) is an ISG 
whose activity is initiated by double-stranded RNA structures that can be presented by 
double stranded RNA viruses or single-stranded RNA transcripts which possess a 
significant double-stranded character.2 The activated OAS1 enzyme interacts with and 
polymerizes ATP to produce a series of unusual 2’ -5’ – phosphodiester linked 
oligoadenylates (2-5A). 2-5A in turn activates the latent ribonuclease RNaseL to form a 
catalytically active RNaseL  which degrades RNA.3  Thus, an activated OAS1-RNaseL 
system can lead to the degradation of viral and cellular RNA 4, inhibit  protein synthesis 
5, attenuate proliferation 6 and promote apoptosis.7  
OAS1 is the rate limiting enzyme in RNaseL activation, a well-known familial 
PCa tumor suppressor gene. 8-10 However, RNaseL has not been observed to contribute to 
sporadic cases of PCa.8 OAS1 has been reported to act independently of RNaseL, 
effecting cellular events such as, cell growth and differentiation. 11Additionally, evidence 
of pro-apoptotic activity demonstrated by in vitro interaction with B-cell lymphoma 2 
[Bcl-2] and extra-large B-cell lymphoma [Bcl-xL] has been found to be regulated by the 
specific isoform of OAS 1 (p48/isoform 3) that is generated through alternative splicing.
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12 Therefore, an alteration of OAS1 function and/or expression could attenuate RNaseL 
function, as well as alter cell growth and apoptosis in an RNaseL dependent and 
independent manner. 13 
 OAS 1 isoforms (p46 and p48), with different ATP polymerization activity are a 
result of a splice site single nucleotide polymorphism (SNP), rs10774671. Non-
synonymous polymorphisms, rs10774671 and rs2660 present in the last exon of OAS 1 
have been associated with susceptibility to viral infections such as herpes simplex 1 14, 
West Nile Virus, 15 Influenza A, 16 and increased incidence to autoimmune diseases such 
as multiple sclerosis, 17-18 and type 1 diabetes. 19-20  Studies have demonstrated that 
multiple low penetrant mutations, such as those presented in a haplotype can confer 
cancer susceptibility; 21 however, association studies of OAS1 polymorphisms with 
prostate cancer susceptibility are limited.  
In this study we integrate the known functional polymorphisms in a gene with 
risk, disease modalities, racial disparities and its molecular mechanism in PCa, a 
significant step forward. We specifically investigate the genetics of OAS1 and its effect 
on PCa phenotype. In this study we hypothesize that OAS1 expression or enzyme activity 
required to generate an anti-tumor response is attenuated in prostate cancer due to single 
nucleotide polymorphisms that are also associated with race. To investigate this 
hypothesis the following aims were proposed:  
1. Investigate the association between OAS1 germ line variations with prostate cancer 
racial disparities. 







2.1 Prostate and Prostate Cancer 
The prostate gland is a structure that makes up part of the male reproductive tract, 
located between the bladder and the penis, just in front of the rectum. 22 The typical 
healthy prostate weighs about 11 grams and its primary function involves controlling the 
secretion of fluid that nourishes and protects sperm. 22-23 The urethra runs through the 
center of the prostate; during ejaculation, the muscles of the prostate gland squeeze 
seminal fluid into the urethra expelling it with sperm as semen. 23  
The adult prostate shown in Figure 1 is comprised of four major zones, the 
peripheral zone, the central zone, the transition zone and the anterior fibromuscular 
stroma 22, 24. The significance of prostate architecture is based upon the relationship of 
these zones to prostatic disease. The peripheral zone, the largest region of the normal 
adult prostate, is located on the posterior side. The peripheral zone is the origin of most 
carcinomas and prostatic intraepithelial neoplasia (PIN). 22 The central zone is posterior 
to the stromal region making it a paired region. Interior to the central zone is the 
transition zone, which constitutes two small lobules that border the prostatic urethra and 
is representative of the region where benign prostatic hyperplasia (BPH) primarily
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originates. 22, 24 BPH is a nonmalignant overgrowth that is fairly common among aging 
men, not to be confused with prostate carcinoma which arises primarily in the peripheral 
zone. 25  
Homeostasis in the normal prostate is maintained by low rates of proliferation and 
low levels of apoptosis. Prostate cancer is the disturbance of this balanced state26 
Metastatic prostate cancers display approximately 60% decrease in the rate of apoptosis 
in comparison to normal prostate tissue. 27-29 The American Cancer Society estimates a 
total of 161,360 new cases and 26,730 deaths initiated by prostate cancer in the United 
States for 2017. Improvements in research and technology have allowed for earlier 
screening and diagnostic procedures resulting in the overall decline in PCa incidence. 30 
The mortality of PCa has dropped 3.3% each year over the last decade, with elevated 
overall survival rate from 66% in the 1970s to 99.6% currently. 31 However, 1 in 39 men 
are estimated to die of prostate cancer and it is still the third leading cause of cancer death 
in American men, behind lung cancer and colorectal cancer.  
 
Figure 1. The adult prostate. The three histologically distinct zones shown are the central zone, the 
transitional zone, and the peripheral zone Image taken from https://www.nature.com/articles/nrc2090. 
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2.1.1 Risk Factors of Prostate Cancer 
Prostate cancer (PCa) is a complex, multi-factorial disease that has been 
established as the most common noncutaneous neoplasm amongst men. 32  It continues to 
be a significant factor in morbidity and mortality in the USA.33 Age, race and family 
history of (PCa) are currently the only established risk factors. 34  Among all cancers, 
prostate cancer is one of the most heritable with genetic factors estimated to account for 
42% of the risk. 35 Familial PCa is a genetically heterogeneous disease suggesting that 
many gene loci rather than a specific major susceptibility gene is responsible for its 
predisposition. 36 PCa exhibits vast differences in incidence among populations 
worldwide. African-American (AfAm) men; however, have the highest incidence of PCa 
with a rate that is 60% higher than that of Caucasian (Cau) men and double the mortality 
rate. 37 Studies have shown that genetic differences may contribute to higher PCa 
incidence in AfAm men in the USA. 38 An understanding of the genetic risk factors for 
cancer thus has practical implication for public health efforts in terms of identifying high 
risk individuals to develop better treatment regimens and early intervention strategies. 
2.1.2 Genetic Disposition in Prostate Cancer Progression 
The genetic predisposition of PCa plays a vital role in the progression of this 
disease as studies have shown that most cases of prostate cancer incidence are considered 
hereditary.36 There are variety of hallmark susceptibility genes that contribute to PCa 
initiation and progression. Genes such as PTEN, 39 ERK/MAPK, 40 and EZH2 41 which 
control tumor suppression, signaling molecules and epigenetic drivers can become 
inactivated, dysregulated, silenced or mutated in cancers. Inherited variations found in 
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genes such as BRCA1, BRCA2, and HOXB13, which are involved in DNA damage 
repair and gene regulation have been identified as major candidate genes related to 
prostate cancer risk. 42-43 
2.1.3 Single Nucleotide Polymorphisms in Prostate Cancer and Genome Wide 
Association Studies 
Single nucleotide polymorphisms (SNPs) are attractive biomarkers in cancer risk 
assessment, screening, staging or grading and have been central to studies to link genetics 
to disease. Polymorphisms are defined as a change in a single nucleotide in the genome 
that account for common variations (>1% in the populations) in DNA sequences between 
members of the same species. There are roughly 10 million SNPs identified in the entire 
human genome, which on average occur every 300 nucleotides.44  
Genome-wide Association Studies (GWAS) are defined as the investigation of a 
genome-wide set of genetic variants amongst different individuals to observe if any 
variant is associated with a trait. This observation is carried out through a series of 
statistical association tests between genotype and phenotype on hundreds of thousands to 
millions of SNPs at a time in order to find genes that contribute to human diseases or 
non-disease traits. 45 Currently, GWAS conducted amongst multiple ethnic groups have 
identified more than 100 gene loci that are significantly associated with prostate cancer 
susceptibility (e.g. 2p15, 3p12, 6q25, 7p15, 7p21, 8q24, 9q33, 10q11, 10q26, 11q13, 
17q12, 17q24.3, 19q13, and Xp11). 46-47 8q24 region is currently considered the most 
important susceptibility region for PCa, especially amongst men of African descent 
which accounts for about 8% of the two-fold increase in risk observed in first degree 
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relatives. 47-48 Other risk loci studied by GWAS include prostate-specific genes (PSA, 
MYC, and AR etc.), 49-51 and inflammation genes (LILRA3, RNase L, and TLR4 etc.). 52-
54 The vastness of the human genome has the potential to uncover more risk loci 
associated with PCa and correlate risk with their biological significance. In addition to 
uncovering risk loci, GWAS has afforded researchers an expansion from small scale 
candidate gene studies, which focus on fewer genes and smaller population sizes (<1k) to 
a broad spectrum whole genome analysis amongst larger population sizes (>1k).  
2.1.4 Haplotypes and Linkage Disequilibrium in Prostate Cancer 
Although the analysis of individual SNP’s with disease association has developed 
significantly in recent years, research has begun to demonstrate that this approach may be 
limited when trying to understand a multifactorial disease such as prostate cancer. 
Therefore, haplotype-based association studies have been proposed as a powerful and 
comprehensive approach in identifying causal genetic variation underlying complex 
diseases such as cancer. 55  
The human genome is composed of a series of ‘haplotype blocks’, which are a 
specific set or group of alleles observed on a single chromosome. 56 The nonrandom 
association of alleles, defined as linkage disequilibrium (LD), allows for the observation 
of the ability of these haplotype blocks to maintain LD or undergo LD decay in the 
presence of disease and disease risk. 57 Linkage analysis has been phenomenally 
successful in localizing Mendelian disease genes.58 Thus LD mapping holds substantial 
appeal considering there is a great demand to resolve the genetics of complex diseases.59 
LD testing is usually carried out as a case-control comparison in which marker 
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frequencies are compared in samples of affected individuals and unaffected controls.59 
Understanding LD in prostate cancer could provide a stronger understanding of gene to 
gene interactions connecting haplotype blocks in various genes that have been associated 
with hormone and immune response, DNA repair, cell survival, and metabolism. 
2.2 Inflammation in PCa 
Chronic inflammation is notorious for its contribution to several forms of human 
cancers (cervix, bladder,  liver, stomach, esophagus, and colon), with an estimated 20% 
of adult cancers attributed to chronic inflammatory conditions caused by infectious 
agents, chronic noninfectious inflammatory diseases and/or other environmental factors.27 
There are even reports of bacterial species known to infect the human prostate and induce 
inflammation, and many of these organisms have been identified from studying patients 
with bacterial prostatitis. 27 During inflammation there is concentrated induction of cells, 
including dendritic cells, CD8+ T-lymphocytes, CD4+ T-lymphocytes, and natural killer 
cells that are triggered to prevent immune evasion and/or progression of diseases. 60 An 
inflammatory response is typically known to be protective against cancer progression and 
initiation; however, there are reports on how acquired deficiencies among immune 
interferon pathways can contribute to the tumor microenvironment (TME) of cancers. 
PIN is considered the precursor of prostate cancer due to its low to high grade 
lesions that are characteristically localized in the prostate ducts. 29, 61 In PIN and early 
invasive carcinomas there is a 7 to 10-fold increase in proliferation. 26 A study conducted 
by Wang et al. 2009, demonstrates a morphological transition of proliferative 
inflammatory atrophy (PIA) to PIN and from PIN to prostate cancer.62 PIA is 
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characterized as a benign lesion containing genetic instability that leads to an imbalance 
between proliferation and apoptosis. 63 This genetic instability induced by chronic and 
recurrent prostate inflammation leads to the initiation and progression of PCa. 62-63 
In many cases a pro-inflammatory TME is influenced by a complex mixture of 
malignantly transformed cells, immune cells and stromal cells that fulfill different 
functions which ultimately promote cancer development, progression and metastasis.60 
The TME is constantly undergoing changes in accordance to the growth of the tumor.64 
One of the most significant changes to the TME instigated by inflammation is the 
phenomenon of hypoxia which is characterized by the lack of blood transported nutrients, 
proton enrichments, the presence of reactive nitrogen species (RNS) and other byproducts 
released from the activated tumor cell metabolism.60 This metabolic reprogramming, 
which takes place in the cytosol of tumor cells leads to a shift to aerobic glycolysis most 
commonly known as the Warburg Effect. 60, 65  
2.2.1 Interferon (IFN) and IFN Pathway in Prostate Cancer  
The innate immune system controlled by interferons (IFNs) establishes the first 
line of host defense during infection and is critical to early recognition and subsequent 
triggering of a proinflammatory response to invading pathogens. 66 IFNs are a family of 
cytokines participating in innate immunity that exhibit anti-tumor behavior due to their 
anti-proliferative, immunoregulatory and apoptotic properties. 67  
IFN have been designated into three distinct classes: types I, II, and III,  which are 
classified according to the receptor complex they signal through.68 Three IFN-λ 
molecules comprise Type III INFs that are called IFN-λ1, IFN-λ2 and IFN-λ3 (also 
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known as IL29, IL28A and IL28B. 69 Type II class of IFN is comprised of a single IFNγ 
protein product which binds the IFNγ receptor (IFNGR) complex, and mediates the 
production of activated T-cells and natural killer cells as an immune defense to pathogens 
other than viruses.70 Type I INFs are the largest subgroup of INFs containing a total of 13 
protein products which include key regulators in immune response such as, IFNα, IFNβ, 
IFNκ, IFNɛ, IFNο, IFNτ and IFNδ, that are incorporated during viral defense. 71 IFNs and 
IFN-stimulated genes (ISGs) are often de-regulated/ silenced/ mutated in many cancers 
including prostate cancer. Type I INF antiviral pathways like OAS1, Protein kinase 
RNA-activated (PKR), and MxA have been implicated as determinants of cancer 
initiation, shown in Figure 2. 68 
 
Figure 2. Focused acute inflammatory/anti- viral pathways in prostate cancer. 
The up regulation of genes within the acute inflammatory pathway by IFN can 
protect normal cells due to elevated immune-surveillance.61-62, 72-80 Loss of this immuno-
surveillance or onset of “immune senescence” can lead to BPH and cancer. 81 Genes 
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involved in the anti-tumor acute inflammatory pathway such as, interferon (IFN) and IFN 
pathway (such as TRAIL) 82-83 that are down-regulated in PCa are of significant interest 
in prostate cancer etiology, making them logical candidates as genetic determinants of 
PCa. 
2.2.2 RNaseL 
The most notable of acute-inflammatory genes in relation to PCa is the tumor 
suppressor Ribonuclease L (RNaseL). 7, 9, 13-14, 16, 67, 80, 84-91 RNaseL (1q24-25) encodes a 
latent endoribonuclease that is required for RNA stability and is a component of the 
interferon inducible OAS-RNA degradation pathway activated upon viral infection. 88 
Acting as a tumor suppressor, 84, 88, 90 RNaseL is also a candidate hereditary PCa gene, 7, 
89, 92 providing direct evidence that the inflammatory pathway is involved in PCa 
etiology. Genetic variants within RNaseL are typically associated with hereditary prostate 
cancer cases whereas RNaseL mutations in sporadic prostate cancer have not been 
observed. 8, 89, 93 These findings are highlighted in a study conducted by Liang Wang et 
al. 8 making the association between germline variants apart from RNaseL and sporadic 
PCa of significant interest. 
2.2.3 Upstream Regulators of RNaseL 
The only known activators required for RNaseL function are members of the OAS 
family of proteins.94 These enzymes in conjunction with RNaseL demonstrate pro-
apoptotic and anti-proliferative properties.95  Thus, IFN regulated OAS, which is the rate 
limiting step the activity of the potent tumor suppressor RNaseL, could contribute to 
sporadic PCa cases or hereditary PCa not associated with RNaseL germline mutations. 
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2.3 Oligoadenylate Synthetase (OAS) Gene Family 
In humans, displayed in Figure 3, the OAS gene family is composed of four genes 
on locus 12q24.1-q24.2: OAS1, OAS2, OAS3 and OASL. 96 This family of genes 
belongs to the nucleotidyl transferase superfamily that are collectively known as the 
double-stranded RNA (dsRNA)-binding oligoadenylate synthetases.97 Each OAS gene 
consists of a conserved core OAS unit composed of five translated exons and their 
splicing isoforms (exons A–E, Fig. 3A) which comprise the cohort of 10 homologous 
proteins either known to mediate or be implicated in 2′,5′-linked iso-RNA (2-5A) 
synthesis in human cells. 97 OAS1 has one unit, whereas OAS2 and OAS3 have two and 
three units, respectively (Fig. 3A). All three genes encode and activate 2–5A synthetases. 
The additional OAS1 and OAS2 isoforms have different C-termini generated by alternate 
splicing. OAS2 and OAS3 are most likely due to gene duplication of exons A-E of OAS1 
(Fig. 3A). OAS1 and OAS2 proteins produce (2-5A)3  that activates RNaseL. 
98 OASL’s 
2-5A synthesis activity has not been demonstrated and presently it is classified as 
catalytically inactive.97, 99 A study conducted by Yize Li et al. established, through 
comparisons of 2-5A synthesis between A549 cell lines knock downs of OAS1 and 
OAS3, that OAS3 is the main activator of RNaseL upon viral infection and interferon 
stimulation. 95 Additional inquiry of RNA expression databases of the human prostate 
supplied by the Human Protein Atlas (HPA), (Genotype-Tissue Expression) GTEx and 
Functional annotation of the Mammalian Genome (FANTOM5), revealed that OAS3 
RNA expression is significantly lower than OAS1 RNA expression in healthy prostate 
tissue implicating OAS1 as the most enzymatically active protein in that tissue. 100 It is 
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possible that in the absence of OAS3, OAS1 is not as efficient at removing virally 
infected cells despite its well reported enzymatic activity. 101 Additionally, there are 
reports that primary OAS activity in cells is attributed to OAS1. 12 Therefore, the 
characterization of expression and enzymatic activity of OAS1 enzymes in normal 
prostate in comparison to its activity in association to PCa tumor microenvironments 
needs to be explored. 
 
Figure 3. Structural organization of OAS1. A: OAS gene family. The structure of OAS1 gene showing 
isoforms 1 (p46/ E18), 2 (p42/E16) and 3 (p48/ 9-2). Exons A through E are common to all OAS1 
isoforms.  The isoforms 1 (p46) and 3 (p48) contain an additional exon (exon F) at the 3’ end. B: Schematic 
of alternative splicing at the last exon of OAS1 modulated by rs10774671 which generates isoforms p46 
and p48. P46 is generated from the G allele at the splice-acceptor site SNP, whereas, the A allele ablates 
the splice-acceptor site creating a 98bp reading-frame shift that is further downstream, producing the p48 
isoform. C: The relative location of polymorphisms proposed in this study is within this last exon F.  The 
rs2660 is in 5’UTR of p46 but in the coding region of p48.  The rs1131476 and rs1051042 are within the 
coding region of p46 but are lost due to alternative splicing in p48.  D: The resulting amino acid sequences 
of OAS1 p46 and p48 isoform haplotype block polymorphisms. Isoform 1, non-synonymous polymorphism 
at rs1131476 (G to A) produce alanine (A) to threonine (T), proline (P) or serine (S) amino acid change and 
rs1051042 (G to C) results in arginine (R) to threonine (T). Isoform 3, non-synonymous polymorphism at 
rs2660 (G to A) polymorphism generates glycine (G) to arginine (R) amino acid change. 
 
2.3.1 2’-5’ Oligoadenylate Synthetase 1 (OAS1) 
 
The OAS1 gene at the 12q24 region gives rise to three alternatively spliced 
proteins isoforms 1 (p46), isoform 2 (p42) and isoform 3 p48) 3 (Fig. 3A) which are 
distinguishable by the unique peptide at their C-terminal ends with varying molecular 
weights (Fig. 3B and D).  The first 5 exons of the OAS 1 isoforms are identical (A-E); 
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however, p46 and p48 possess an additional exon (Exon F) which is distinctive to each 
isoform due to the splice acceptor site SNP rs10774671 (Fig. 3A).  The GG genotype at 
rs10774671 generates p46 whereas the AA genotype generates p48 (Fig. 3A, B and C). 
The location of SNPs rs1131476, rs1051042 and rs2660 in context of each isoform (Fig. 
3C) and the contribution of each SNP in generating a unique peptide (Fig. 4D) suggests 
these SNPs may alter function of the OAS1 isoforms. 
OAS1 enzyme demonstrates pro-apoptotic and anti-proliferative properties.13  As 
previously stated, IFN regulated OAS1 appears to be the rate limiting enzyme in RNaseL 
activity and its generation of an effective inflammatory response. However, the role of 
OAS1 as a potent tumor suppressor independent of RNaseL in PCa is not known. OAS1 
is induced by both type I and type II INFs and as an integral part of the acute-
inflammatory/innate immunity pathway it is required for an effective anti-viral response.3 
Studies have also shown that OAS1 negatively regulates proliferation.88  Figure 4 
demonstrates that OAS1, in the presence of double stranded RNA structures, such as viral 
genomes or single stranded RNA transcripts with double stranded character, converts 
ATP to a series of unusual 2’-5’ –phosphodiester linked oligoadenylates or 2-5A 
[(A2’p9)n A or 2-5A for short]3. 2-5A in turn is required for the activation of RNaseL.85 
In spite of its significance as a tumor suppressor and in RNaseL activation, the 
expression, activation, mutations or polymorphism of this key enzyme (2-5 OAS) are not 







Figure 4. OAS/RNaseL pathway. OAS is activated by dsRNA. Activated OAS polymerizes ATP which in 
turns activates latent RNaseL to active RNaseL then Active RNaseL degrades viral RNA. 
 
2.3.2 2’-5’ Oligoadenylate Synthetase 1 (OAS1) Function and Structure 
The reason for multiple isoforms of OAS1 with essentially similar function 
remains unknown. Some evidence demonstrates pro-apoptotic activity of OAS1 isoform 
3 (p48)) (in vitro interaction with Bcl-2 and Bcl-xL) 102 but not in knockout mice. 103 
Although elements unique to particular isoforms could account for their differential 
response to transcription factors such as NFκB and IL-6.104 Only one mRNA species has 
been identified for human OAS3 and it has shown to predominantly produce (2-5A); 
however, there are conflicting studies on their role as an activator of RNaseL.95  
A study conducted by Jesse Donovan et al. synthesized cocrystallized human 
OAS1 with dsRNA containing 18 bp and a substrate analog, 2′-deoxy ATP (dATP), that 
establishes the molecular basis for dsRNA recognition by OAS1 of how OAS1 
recognizes and recruits dsRNA to regulate 2-5A synthesis.97 From that study they 
established OAS1 as a  ternary complex when joined with a dsRNA (at least 18 bp in 
length) and 2′-deoxy ATP (dATP).97 The crystal structure of the active complex bound 
with dsRNA reveals that OAS1 recognizes dsRNA using a unique protein surface by way 
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of two dsRNA-binding sites located ∼30 Å apart also recognized as N- and C-terminal 
lobes of OAS1.97 Upon dsRNA binding OAS1 distorts and bends the ribophosphate 
backbone of dsRNA.97 Additionally, two Mg2+ ions within the crystallization structure 
are required for the recruitment of dATP to OAS1 thus creating the 2-5A oligomers that 
are required to activate RNaseL.97  
2.3.3 OAS1 Activation by Cellular mRNA 
In PCa cells, it has been revealed that at least two non-viral RNAs can activate 
recombinant OAS1 in an in vitro assay: mRNAs for Raf kinase inhibitor protein (RKIP) 
and poly(rC)-binding protein 2 (PCBP2), discovered through an in vitro recombinant 
OAS1- cellular RNA interaction approach .105 Authors speculate that RKIP mRNA itself 
may exert an apoptotic effect by activating the OAS/RNaseL pathway that is completely 
independent of the encoded protein. 106 PCBP2 is involved in mRNA stabilization and 
controls both translational initiation and transcription.106 These observations implicated 
that OAS1 can be activated by multiple pathways and may not necessarily require a viral 
genome.  
2.4 Genetic Variation (Single Nucleotide Polymorphisms) in OAS1 
Genetic variations caused by SNPs are of particular interest due to their ability to 
classify tumors and identify therapeutic targets required in the description of the genetic 
changes underlying cancer. 107 Overall there are more than 50 polymorphic markers 
known to exist in the OAS1 gene. Those of interest are splice site polymorphisms 
(rs10774671) and polymorphisms that are non-synonymous (resulting in a different 
amino acid and hence slightly different protein), rs1131467, rs1051042 and rs2660. Two 
17 
 
of these polymorphic markers (rs1131467 (exon C) and rs2660 (Fig. 3C)) are well 
studied and demonstrate association with various diseases.  
2.4.1 2-5 OAS1 Haplotype Block 
A preliminary case-control analysis reported the AA genotype of SNP rs2660 to 
be linked with PCa susceptibility with increased association when stratified by age and 
race. 108 In addition, the GG genotype at rs2660 among Caucasians was significantly 
associated with normal prostate suggesting it as a protective genotype.  Since the 
inference of an individual SNP in association to PCa susceptibility is limited, we sought 
to expand our investigation of genetic variations within the last exon of OAS 1. Previous 
findings have shown that rs2660 is in linkage disequilibrium (LD) with rs1131476, 
rs1051042 and the splice site polymorphism rs10774671, all of which were collectively 
identified as a haplotype block.12 Population frequency data, shown in Figure 5, from 
NCBI SNP database suggests that the two most studied OAS1 SNP (rs10774671 and 
rs2660) previously reported to be in LD 109 are in LD in Caucasian (Caucn) population 
but not in African Americans due to LD decay. The lack of LD in (AfrAm) men can have 
profound effect on OAS1 splicing and subsequent protein products (Fig. 3D).  Therefore, 
a genotypic and haplotype-based association analysis of OAS1 SNPs (rs10774671 [G-
>A], rs1131476 [G->A], 1051042 [G->C], and rs2660 [G->A]) may serve as powerful 
and comprehensive approach to identify causal genetic variation underlying a 




2.4.2 OAS1 Enzymatic Activity in Prostate Cancer 
Studies have demonstrated OAS1 activity in DU145 cell line using Polyinosinic: 
polycytidylic acid (poly I:C) bound activated sepharose beads.110 DU145 has been shown 
to be abundant in the expression of p46 isoform of OAS1, in comparison to other prostate 
cancer cell lines such as LNCaP.110 This demonstration is of particular significance 
because the phosphates generated by the OAS1 enzymatic reaction is coupled with 
conversion of the substrate 2-amino-6-mercapto-7-methylpurine ribonucleotide 
(methylthioguanosine, a guanosine analogue; MESG) to a purine base product, 2-amino-
6-mercapto-7-methylpurine and ribose1-phosphate via a catalyst purine nucleoside 
phosphorylase (phosphorylase). 110 The absorbance of the purine base product is 
measured at 360 nm. The higher levels of phosphates detected in the DU145 cell line 
indicates more activity of OAS1 in this prostate cancer cell line. 110 
 
Figure 5. Genotype of the proposed haplotype block and linkage disequilibrium (LD) between rs2660 and 
rs10774671. A: Haplotype block from two studies (PERLEGEN and SNP500) in NCBI dbSNP database. 
B: Linkage disequilibrium (LD) between rs2660 and rs10774671 via r2 analysis of combined (Caucasian 
and African-American), Caucasian (Caucn) and African American (AfrAm).  r2 values (indicated in the 
diamond) less than 0.5 suggests that the SNPs are not in linkage disequilibrium.  The lowest value is 




2.5 OAS1 and Disease Associations 
The OAS1 gene locus and its polymorphisms have demonstrated increased 
susceptibility to an array of autoimmune diseases. A study conducted by O'Brien M. et al. 
confirmed splice acceptor site SNP rs10774671 AA genotype with conferred 
susceptibility to multiple sclerosis (MS) and the GG genotype protected against increased 
disease activity contributing to MS.18 Additionally, Faedetz M et al. showed haplotypic 
association of the G allele at rs10774671 and the A allele at rs3741981 with the 
susceptibility to MS.17 Rs10774671 has also been linked to type I diabetes (T1D) a 
disease characterized as autoimmune destruction of the pancreatic beta-cells. 19-20, 111  
Susceptibility to Sjögren's syndrome (SS), a disease that causes an immune defense 
against healthy cells that produce saliva and tears causing dryness of the mouth and eyes, 
has been shown to be influenced by rs10774671 which was confirmed through meta-
analysis of two independent cohorts (Pmeta = 2.59 × 10-9; odds ratio = 0.75; 95% 
confidence interval = 0.66-0.86).112 Most recently the OAS1 gene locus was significantly 
up-regulated among individuals with type 2 diabetes (T2D) and T2D related infections. 
113-114 Once characterized as metabolic disease in comparison to T1D it has been shown 
that susceptibility to T2D is influenced by tumor necrosis factor-α inflammation caused 
by the presence of fatty tissue, influenced by the OAS1/RNaseL pathway,115 which 
increases the level of fatty acids in the blood leading to fatty liver disease, high 
cholesterol, high blood pressure and significantly increased insulin resistance in the body. 
114, 116 Lastly, a study of systemic lupus erythematosus (SLE), a chronic autoimmune 
disease with multiple organ involvement, in which auto-antibodies induce tissue damage, 
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identified OAS1 as 1 of 10 common marker genes associated with SLE.117 Additionally, 
autoimmune diseases with which OAS1 has been associated have also been implicated in 
several studies to increase susceptibility to cancer. 118-121  
2.5.1 OAS1 and Infectious Diseases 
The importance of OAS1 proteins in the human antiviral response is highlighted 
by genetic studies designating it as an antiviral enzyme. Variations of OAS1 SNPs, 
specifically rs10774671, have shown that they can confer increased susceptibility to 
hepatitis C, 122-123 influenza A, 16, 95 flavivirus, 124-125 West Nile virus, 15, 91, 95, 124 
respiratory epithelial cell syncytial virus, 126 ocular herpes simplex virus type 1,14 SARS, 
127 Human enterovirus 71 (EV71) and coxsackievirus (hand, foot and mouth disease).128 
OAS1 polymorphism rs2285934 has also been associated with the severity of liver 
disease in HIV/HCV-co-infected patients, suggesting a significant role in the progression 
of hepatic fibrosis. 129 OAS1 SNP rs1131476 is associated with chronic hepatitis B 
(CHB) and hepatitis B e antigen-negative chronic hepatitis B.130 The most notable of viral 
association with OAS1 polymorphisms is with increased viral persistence of Human 
Papilloma Virus (HPV), which has been linked to cervical cancer and in some cases 
prostate cancer. 131-132 
2.5.2 OAS1 and Aging 
A study demonstrating an age dependent decrease in OAS1 enzyme activity (in 
liver and brain) was observed in aging rats. 133 These results are significant because aging 
is a well-known factor attributing to increased PCa risk and progression. Apart from our 
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study, 108  there is no direct evidence that demonstrates OAS1 SNP, expression/activity in 
normal prostate or PCa. 
2.5.3 OAS1 and Cancer 
IFN induced apoptosis is dependent on OAS1 expression and requires functional 
BRCA1 and STAT1 in breast cancer cells. 13 Inhibition of OAS1 by siRNA in NIH/3T3 
fibroblasts induces a metastatic phenotype such as anchorage-independent cell growth 6. 
Ectopic OAS1 expression results in increased anti-viral activity and growth suppression 
in a glioblastoma cell line (T98G) 134 and growth arrest and differentiation in myeloid 
cells.11 As previously mentioned, OAS1 polymorphisms have been linked to cervical 
intraepithelial neoplasia grade 3 (CIN3), the direct precursor of cervical cancer. 131 Thus, 






MATERIALS AND METHODS 
 
3.1 Sample Set 
The genotyping protocol and use of retrospectively collected human samples for 
this study were approved by the Clark Atlanta University institutional review board. 
Genotyping was performed on a total of ~426 samples (Table 1). The samples were 
acquired from resources described earlier 108 and from the in-house Center for Cancer 
Research and Therapeutic Development bio-repository core.  All samples were stored at -
80°C until analysis. De-identified comprehensive clinical information regarding age, 
ethnicity and stage was available for all samples. Additional OAS1 haplotype genotyping 
data for 172 Caucasian (CEU) and 90 African-American (ASW) healthy males was 
acquired from the publicly available 1000 Genomes and HapMap projects.  This dataset 
was used to increase the power of statistical analysis which was determined as described 
earlier. 108  Samples from the 1000 Genomes and HapMap projects did not contain 
publicly available age data. Consolidated analysis was thus performed on a total sample 
688 samples. 
3.2 RNA Preparation and RT-PCR 
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) from cultured 
prostate cancer lines. 108 The reverse transcribed RNA was used per the protocol 
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supplied by the manufacturer. RNA (4μg) was reverse transcribed to a final volume of 
25μl per standard protocol (RT Master Mix: 1.25mM each of dNTP’s, 250ng oligo dT 
(Promega, Madison, WI), 10mM dithiothreitol, and 200U MMLV reverse transcriptase in 
vitro) in the MMLV first-strand synthesis buffer (Invitrogen)). Initially, RNA in DEPC 
water was denatured for 10 mins at 65℃ for 10min, then cooled on ice for 2mins before 
addition of RT Master Mix. The reverse transcriptase reaction was carried in thermo 
cycler at 42℃ for 1hr and 95℃ for 5 minutes.  The OAS1 isoform specific (p46 and p48) 
primers described earlier 108 were used to determine respective isoform gene expression 
levels.  
3.3 Genotyping 
Genomic DNA was isolated from cultured cells or buffy coat using AquaPure 
total genomic DNA isolation kit (Bio-Rad). Genomic PCR was carried out in a 25ul PCR 
reaction that consisted of 12.5ul GoTaq Colorless Master Mix (Promega), 30ng genomic 
DNA and 400pm of 5’ and 3’ primer each. The PCR was carried out for 30 cycles with 
annealing temperatures of 94°C and 53°C. The following primers were used for 
sequencing (Ref. seq.: NC_000012.11) Forward 5’-GCT CAC TGA ACT CAG CTG 
CA-3', Reverse 5’-GGA TAG AGG GCA TAG AAG GC-3’ spanning all SNPs 
(rs10774671, rs1131476, rs1051042, and rs2660) within the last exon of OAS1.  
3.4 SNP Detection 
The rs10774671, rs1131476, rs1051042, and rs2660 polymorphisms were 
detected by sequencing the PCR amplicon spanning the SNPs using the primer pairs. 
PCR reaction was first analyzed on 1.5% agarose gel to confirm specificity and quality of 
the reaction in terms of band size and absence of any background PCR product. Once 
24 
 
confirmed, the remaining PCR product was cleaned using ExoSAP-IT (USB) before 
sequencing on the AB sequencer (DNA sequencing Lab, Morehouse School of Medicine, 
Atlanta, GA). The sequences were manually scanned using ABI sequence scanner and 
checked using Mutation Surveyor®. 
3.5 p48 Antibody Production and Purification 
An antibody specific for OAS1 p48 isoform was not commercially available at the 
time of this study.  We therefore developed a rabbit polyclonal antibody (Pacific 
Immunology Inc., Ramona CA) specific to p48 using the following isoform specific C-
terminal peptide: “TQHTPGSIHP TGRRGLDLHH PLNASASWGK GLQCYLDQFL 
HFQVGLLIQR QSSSVSWCII QDRTQVS”. The peptide (antigen) was synthesized, 
characterized and conjugated to KLH and used to immunize 2 rabbits. The pre-immune 
serum and post-immunization bleeds were used for antibody titer in an ELISA based 
assay (Pacific Immunology).  The post-production bleeds from two rabbits were used for 
IgG purification and characterization.  Briefly the 40ml serum each from the 2 rabbits 
was first precipitated with 40-50% ammonium sulfate.  The resulting immunoglobin 
precipitate was affinity purified using Montage® Antibody Purification Kit and Spin 
Columns with PROSEP® -A Media (EMD Millipore). The purified IgG was checked for 
antigen specific binding in ELISA (immobilized peptide) and western blot analysis 
(peptide alone). The purified IgG was used for western blot and IHC analysis. 
3.7 Western Blot Analysis 
30 µg of total protein was size fractionated on 4-20% SDS-polyacrylamide gel 
and subsequently blotted onto a nitrocellulose membrane (Whatman). The blotted 
nitrocellulose membrane was subjected to western blot analysis using OAS1 antibodies 
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(p46: sc-49833 Santa Cruz) and p48 (in-house). After washing with 1x PBS, 0.5% Tween 
20, the membranes were incubated with horseradish peroxidase (HRP) coupled secondary 
antibody against rabbit IgG and visualized using the Super Signal West Dura Extended 
Duration Substrate (Thermo Scientific) on Fuji Film LAS-3000 Imager. 
3.8 Immunohistochemistry 
Prostate cancer tissue microarrays (PCa-TMA were used to investigate OAS1 
isoform specific expression.  The PCa-TMA and the method used to detect OAS1 
isoform specific expression was essentially similar to our earlier study135.  Briefly, the 
PCa-TMA slides were de-paraffinized and antigens retrieved by autoclaving in 0.01 M 
sodium citrate buffer pH 6.0 at 121C/20 psi for 30 min. The slides were then blocked for 
peroxidase activity in 3% H2O2 (in PBST: PBS with 0.05% Tween 20) for 10 min and 
then blocked in 10% goat serum (PBST with 1% BSA) for 2 h at room temperature. The 
blocked sections were incubated overnight at 4°C with primary antibody (1% BSA in 
PBST). The slides were then washed twice with PBST for 5 min each, and then incubated 
with secondary antibody (1% BSA in PBST, 1:1000, SA1-9510, HRP- goat anti-rabbit; 
Thermo Scientific, Rockford, IL) for 1h. The slides were washed with PBST for 5 min 
and stained with DAB for 2 min. Slides were then finally counterstained in hematoxylin 
and mounted with Immuno-mount (Thermo Scientific), examined and photo-micrographs 
taken using the Zeiss fluorescent microscope with an AxoimCam version 4.5 imaging 
system. 
3.9 Statistical Analysis 
Each polymorphism was tested for its association with prostate cancer. Odds 
ratios (ORs) and 95% confidence intervals (CIs) were calculated for the genotype in 
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association with prostate cancer using logistic regression analysis. 136 Correlations 
between genotype distribution and individuals stratified by race were analyzed using the 
model described above. The NCSS 11 Statistical Software (NCSS, LLC. Kaysville, Utah) 
packages were used for statistical analyses. After stratifying the data by group and race, 
regular logistic regression models were used to calculate the ORs and 95% CIs using the 
control group as a reference. Logistic regression models were used to assess the 
interaction between disease and genotype.  Haplotype analysis was performed as 
previously explained 137. P values < .05 were considered statistically significant 137.  
Semi-quantitative analysis of OAS1 isoform specific expression in normal prostate, BPH 
and prostate cancer (grade I-III) was evaluated by non-parametric Kruskal-Wallis 
statistics (non-parametric one-way ANOVA) followed by Mann-Whitney test (GraphPad 
Prism v5). 
3.10 Application and Acquisition of Genome Wide Association Studies (GWAS) 
GWAS datasets require an official request for access to The Database of 
Genotypes and Phenotypes (DbGaP) from the Principal Investigator (PI) by submitting a 
Data Use Certification (DUC) to the appropriate NIH Data Access Committee (DAC) for 
approval. Listed are the following DbGaP studies utilized for analysis and the DUC 
requests provided by Nathan Bowen Ph.D.:  
1) A Multiethnic Cohort (MEC) Genome-wide Scan of Prostate Cancer -DbGaP 
Study Accession: phs000306.v3. p1. 138-139 Requestor: Bowen, Nathan Affiliation: 
CLARK ATLANTA UNIVERSITY Project: Investigating somatic mutations in prostate 
cancer from African-American men. Date of approval: Jul 07, 2011.  
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Funding support for the GENEVA Prostate Cancer study was provided through the 
National Cancer Institute (R37CA54281, R01CA63464, P01CA33619, U01CA136792, 
U01CA98758, and RC2 CA148085) and the National Human Genome Research Institute 
(U01HG004726). Assistance with phenotype harmonization, SNP selection, data 
cleaning, meta-analyses data management and dissemination, and general study 
coordination, was provided by the GENEVA Coordinating Center (U01HG004789-01). 




2) Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer GWAS - 
Primary Scan (Stage 1) - PLCO Screening Trial  
DbGaP Study Accession: phs000207.v1. p1. 38 Requestor: Bowen, Nathan Affiliation: 
CLARK ATLANTA UNIVERSITY Project: Investigating somatic mutations in prostate 
cancer from African-American men. Date of approval: Jul 07, 2011. 
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000207.v1.p1#attribution-section  
Research Use Statement: The goal of our research is to identify somatic coding mutations 
that are unique to prostate cancer in African-American men. Access to this dataset will 
enable us to begin to tabulate mutations found in the ethnic groups represented in this 
study. We are in the process of sequencing matched samples of prostate cancer and blood 
from African-American men and will be able to perform comparative analyses of our 
results to those published in this study.  
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Technical Research Use Statement: African-American men are 65% more likely to be 
diagnosed with prostate cancer and more than 2X as likely to die from the disease. We 
are investigating the extent to which the genetic aberrations found in prostate cancers 
from African-American men are similar to or different from those found in the prostate 
cancers of other ethnic groups. 
3.11 GWAS Study Subjects 
The dataset A Multiethnic Genome-wide Scan of Prostate Cancer (MEC) is part 
of the Gene Environment Association Studies initiative (GENEVA, 
http://www.genevastudy.org) containing a total of 4,501 subjects divided into two 
cohorts: Japanese and Latino (n=1,660 Cases:834 Controls:826) genotyped through 
Illumina- Human660W-Quad_v1_A with approximately 592,839 SNPs and African 
Americans (n=2,841 Cases:1,343 Controls:1,498) genotyped through Human1M-
Duov3_B with approximately  1,185,051 SNPs. 138-139  
The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer GWAS 
included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and 
Phase 1B HumanHap240, both from Illumina, San Diego, CA) 2,252 subjects were 
submitted to DbGaP. 38  It contains 1,172 prostate cancer patients and 1,157 controls of 
European ancestry from the Prostate, Lung, Colon and Ovarian (PLCO, 
http://www.cancer.gov/prevention/plco/) Cancer Screening Trial. 38  
3.12 PLINK Hardy Weinberg Equilibrium (HWE)  
We utilized PLINK Whole genome association analysis toolset for HWE analysis and all 
subsequent analysis associated with PLINK. 
Package:     PLINK (plink-1.07-x86_64.zip) 
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Author:      Shaun Purcell 
URL:         http://pngu.mgh.harvard.edu/purcell/plink/  
To generate a list of genotype counts and Hardy-Weinberg test statistics for each SNP, 
use the option: 
plink --file data --hardy 
 
Which creates a file: 
 
     plink.hwe 
 
This file has the following format 
     SNP             SNP identifier 
     TEST            Code indicating sample 
     A1              Minor allele code 
     A2              Major allele code 
     GENO            Genotype counts: 11/12/22  
     O(HET)          Observed heterozygosity 
     E(HET)          Expected heterozygosity 
     P               H-W p-value 
 
An example of the command used to obtain this information is as follows: 





P_c2_subject_level --chr 12 --maf 0.05 --hardy --out 
Under the null hypothesis of no association with the disease, we expect the relative allele 
or genotype frequencies to be the same in control groups. Ex: (AA, AG, GG) after testing 
for HWE SNPs, P-values <0.05 were discarded from the study. 140 
3.13 PLINK SNP Minor Allele Frequency  
To generate a list of minor allele frequencies (MAF) for each SNP, based on all 
founders in the sample: 




will create a file: 
 
     plink.frq 
 
with five columns: 
 
     CHR       Chromosome 
     SNP       SNP identifier 
     A1        Allele 1 code (minor allele) 
     A2        Allele 2 code (major allele) 
     MAF       Minor allele frequency 
     NCHROBS   Non-missing allele count 
 
An example of the command used to obtain this information is as follows:140 
 







ancer_JL_TOP_c2_subject_level --snp rs3741981 --window 100 --assoc 
 
3.14 PLINK Case/Control PCa Association 
To perform a standard case/control association analysis, use the option:140 
plink --file mydata --assoc 
 
which generates a file 
    
  plink.assoc  
which contains the fields: 
     CHR     Chromosome 
     SNP     SNP ID 
     BP      Physical position (base-pair) 
     A1      Minor allele name (based on whole sample) 
     F_A     Frequency of this allele in cases 
     F_U     Frequency of this allele in controls 
     A2      Major allele name 
     CHISQ   Basic allelic test chi-square (1df) 
     P       Asymptotic p-value for this test 
     OR      Estimated odds ratio (for A1, i.e. A2 is reference) 
 
Odds Ratio Odds ratio measures the “odds” of association OR> 1.2: associated with the 
disease OR= 1: no significant association OR< 0.8: not associated with the disease P-
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Value < 0.01 Substantial evidence against our null hypothesis Null hypothesis = 
“exposure” is not related to the disease outcome.   
3.15 PLINK Meta-Analysis, Between MEC and CGEMS  
 
The basic command for meta-analysis is invoked as 
plink --meta-analysis study1.assoc study2.assoc study3.assoc 
 
PLINK expects each file to be a plain-text, rectangular white-space delimited file, with a 
header row. PLINK will search the header row for the columns: 
     
 SNP  SNP identifier 
      OR   Odds ratio (or BETA, etc) 
      SE   Standard error of OR (or user-defined weight field) 
       P   (Optional) p-value from test 
      CHR   (Optional)  
      BP   (Optional) 
      A1   (Optional) 
      A2   (Optional)  
 
For example, consider we have two association files from independent 
studies, s1.assoc and s2.assoc. For example, if the first few rows of s1.assoc were as 
follows: 
   CHR        SNP         BP   A1      F_A      F_U   A2     CHISQ       P      OR       SE      L95     U95 
    22   rs915677   14433758    A   0.1522   0.1842    G    0.1538   0.695  0.7949   0.5862    0.252   2.508 
    22   rs140378   15251689    G  0.02083  0.04762    C    0.4988    0.48  0.4255    1.243  0.03719   4.869 
    22   rs131564   15252977    C   0.1522   0.2619    G     1.625  0.2024  0.5058   0.5401   0.1755   1.458 
    22  rs4010550   15274688    G   0.1364    0.275    A     2.495  0.1142  0.4163   0.5642   0.1377   1.258 
    22  rs5747361   15365080    0        0        0    G        NA      NA      NA       NA       NA      NA 
    22  rs2379981   15405346    G  0.02083        0    A    0.8848  0.3469      NA       NA       NA      NA 
    ... 
 
The command 
plink --meta-analysis s1.assoc s2.assoc 
 
gives the following output 
 
     Performing meta-analysis of 2 files 
     Reading results from [ s1.assoc ]  with 2680 read 
     Reading results from [ s2.assoc ]  with 2655 read 
     2778 unique SNPs, 2557 in two or more files 
     Rejected 1911 SNPs, writing details to [ plink.prob ] 




In general, SNPs across two or more files do not need to be in the same order; also, a 
SNP does not need to feature in all files. By default, meta-analysis will be reported for 
any SNP in two or more files.140 
In this case, SNPs are reported to be rejected from meta-analysis. The reason for this is 
reported in the file 
     plink.prob 
 
which lists the SNP, the file and the problem code, as follows: 
 
     BAD_CHR               Invalid chromosome code  
     BAD_BP                Invalid base-position code  
     BAD_ES                Invalid effect-size (e.g. OR)  
     BAD_SE                Invalid standard error  
     MISSING_A1            Missing allele 1 label 
     MISSING_A2            Missing allele 2 label 
     ALLELE_MISMATCH       Mismatching allele codes across files 
 
The main output is in the file 
 




      CHR         BP         SNP  A1  A2   N        P     P(R)      OR   OR(R)       Q       I 
       22   14433758    rs915677   A   G   2   0.2217   0.2217  0.5823  0.5823  0.4184    0.00 
       22   15252977    rs131564   C   G   2   0.2608   0.2608  0.6665  0.6665  0.4924    0.00 
       22   15274688   rs4010550   G   A   2    0.298   0.3545  0.6748  0.6673  0.2489   24.79 
       22   15462210  rs11089263   A   C   2   0.3992   0.3992  1.3108  1.3108  0.3600    0.00 
       22   15462259  rs11089264   A   G   2   0.4719   0.4719  1.2606  1.2606  0.4079    0.00 
       22   15475051   rs2154615   T   C   2   0.5518   0.5518  1.2876  1.2876  0.7534    0.00 
       22   15476541   rs5993628   A   G   2   0.8014   0.8014  1.0948  1.0948  0.3380    0.00 
       22   15549842   rs2845362   C   G   2    0.865   0.9789  0.9399  0.9854  0.1307   56.23 
 
which has the following fields: 
 
     CHR       Chromosome code 
     BP        Basepair position 
     SNP       SNP identifier 
     A1        First allele code 
     A2        Second allele code 
     N         Number of valid studies for this SNP 
     P         Fixed-effects meta-analysis p-value 
     P(R)      Random-effects meta-analysis p-value 
     OR        Fixed-effects OR estimate 
     OR(R)     Random-effects OR estimate 
     Q         p-value for Cochrane's Q statistic 
     I         I^2 heterogeneity index (0-100) 
 
The effect (OR, or BETA in case of quantitative trait) is with respect to the A1 allele (i.e. 





4.1 Sample Set 
To understand how 2-5 OAS1 SNPs rs10774671, rs1131462, rs1051042and 
rs2660 associate with prostate cancer risk we conducted a case-control study on 688 
samples identified in Table 1. The unrelated clinically defined cancer (N=340) and 
control samples (N=348) were roughly 50% each of the total sample size. The mean age 
of cancer samples (61.4 ± 9.3) and normal samples (59.7 ± 6.3) and were not statistically 
different (P = 0.18465). The populations included in our study consisted of Caucasians 
(n=462) and African Americans (n=226).  
Table 1. Demographics of Samples 
 
*Ages of HapMap and 1000 Genomes samples are not included in the age matching data 
4.1.1 Frequency of rs10774671 Polymorphisms  
In Table 2, we show the distribution of the three observed genotypes of 
rs10774671 (GG, GA, and AA) amongst the samples. Graphical representation of the 
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genotypic distribution of rs10774671 is shown in Figure 6A. The GA genotype was not 
observed in cases but was observed only in 16.68% of the control samples. Because the 
GA genotype was absent in the cases, it was excluded from our PCa association analysis, 
therefore, only GG and AA genotypes were evaluated. Among the controls, P46 (GG) 
and p48 (AA) genotypic frequencies were 34.48% and 32.18% respectively (Fig 6A).  In 
contrast, the GG genotype was found in 95.53% and AA genotype in 6.47% cases (p 
<0.001, OR=1.8; Table 2A).  




*Genotype distribution for all samples, Caucasian samples and African-American samples with 
corresponding odds ratio, 95% confidence intervals and p-values are shown. 
 
These results suggest that the p46 isoform of OAS 1 may be the predominant 
isoform expressed in prostate cancer, and as such representing a potential PCa risk allele. 
Ethnic stratification of the samples exhibited a similar distribution of the GG and AA 
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genotypes between cases and controls. In the Caucasian samples the GG genotype was 
represented amongst 25.93% of the control and 95.93% in the case group (p < 0.001, 
OR=2.36; Table 2). The GG genotype amongst the African-American control samples 
was 48.48% and 87.23% amongst the cases (p = 0.002, OR=1.28 =; Table 2). Overall, 
these results suggest the alternative splicing at rs10774671 does not contribute to PCa 
health disparities, when the samples are stratified by race, but demonstrates a significant 
difference between cases and controls (Fig. 6A). 
 
Figure 6. Percent of distribution of genotypes A: Normalized genotypic distribution of SNP rs10774671 
between a combination of cases and controls (All), cases only (PCa) and controls only (N), all samples 
(Total Population), Caucasians and African Americans. B: Normalized genotypic distribution of SNPs 
rs1131462, rs1051042, and rs2660 between a combination of cases and controls (All), cases only (PCa) and 
controls only (N), all samples (Total Population), Caucasians and African Americans. C: Normalized 
distribution of SNPs rs10774671, rs1131462, rs1051042, and rs2660 as a haplotype between a combination 
of cases and controls (All), cases only (PCa) and controls only (N), all samples (Total Population), 




4.1.2 Frequency of rs1131462, rs1051042, and rs2660 Polymorphisms 
Significant linkage disequilibrium was observed among SNPs rs1131462, 
rs1051042 and rs2660 as they occurred at identical frequencies. For convenience of 
analysis, rs1131462, rs1051042 and rs2660 were collectively represented as GG, GA, and 
AA although rs1051042’s respective genotypes are GG, GC and CC, demonstrated in 
Table 3. Graphical representation of the genotypic distribution of SNPs rs1131462, 
rs1051042 and rs2660 are shown in Figure 6B. Collectively, the GG genotype was 
present in 8.05% of the control samples and 12.94% among the cases, but was not 
significant (p= 0.09, OR 1.5; Table 3).  
Table 3. Association of 2’-5’ Oligoadenylate Synthetase 1 SNPs rs1131462, 
rs1051042 and rs2660 with Prostate Cancer* 
 
*Genotype distribution for all samples, Caucasian samples and African American samples with 




The GA (Controls: 29.89%, cases: 33.53%; p= 0.30, OR=1.12; Table 3) and AA 
(controls: 62.07% and cases: 53.53%, P=.14, OR=0.8; Table 3) genotypes were also not 
associated with PCa.  We then stratified the data by race and noted a similar distribution 
between the GG, GA and GG genotypes among the Caucasian samples; however, there 
was a significant difference when analyzing the African-American samples. The GG 
genotype in the African-American sample set was not present in either the controls or 
cases while the AA genotype was present in 89.39% of the cases and 95.74% of the 
controls, with no significant association with PCa risk (p=0.06, OR 1.07; Table 3). 
Overall, the data for SNP’s rs1131462, rs1051042 and rs2660 revealed no significant 
associations with health or PCa susceptibility (Fig. 6B). In addition, we observed a 
complete absence of the GG genotype in African Americans in both controls and PCa 
effected patients (Table 3).  
4.1.3 OAS1 Haplotype Block 
For further analysis, we sought to understand the occurrence of these 
polymorphisms in their respective haplotype block, shown in Table 4. The haplotypes 
consisting of rs10774671, rs1131462, rs1051042and rs2660 within the sample set were 
GACA, AACA and GGGG (AAGG/AACA was observed in one patient with PCa but 
was removed from the logistic regression analysis). Graphical representation of their 
haplotypic distribution are demonstrated in Figure 6C. The GGGG haplotype, which is 
the reference OAS1 gene, demonstrated a weak association with prostate cancer (all 
samples, OR 1.28, p<0.05) (Table 4). Upon stratification of the samples, the GGGG 
haplotype block lost any association with cancer, possibly due to less than 5% of samples 
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with this haplotype block (Table 4). The AACA haplotype block was significantly 
associated with normal subjects among both Caucasians (OR =0.06612, P < 0.001, Table 
4) and African Americans (OR =0.24, P < 0.001, Table 4). The GACA haplotype; 
however, showed significant association with PCa. Strong association with PCa 
susceptibility was observed among those with the GACA haplotype whose frequency 
increased from 46% among the control to 64% among cases (OR= 2.31, p <0.0001; Table 
4). We then sought out to see how these haplotypes are associated with race. Caucasians 
with the GACA haplotype were 5 times more likely to be affected with PCa and African 
Americans were 1.5 times more likely (P < 0.001; Table 4 and Fig. 6C).  
Table 4. Association of 2’-5’ Oligoadenylate Synthetase 1 SNPs rs10774671, 
rs1131462, rs1051042 and rs2660 as a Haplotype with Prostate Cancer* 
 
*Genotype distribution for all samples, Caucasian samples and African-American samples with 





4.2 Generation and Characterization of the Rabbit Polyclonal p48 Specific Antibody 
We next set out to investigate the expression of OAS1 isoforms (p46 and p48) in 
prostate cancer tissue to confirm the splice site polymorphism rs10774671 genotype. We 
expected the p46 (GG Genotype) and p48 (AA Genotype) (Table 2) expression 
predominantly in prostate cancer and normal samples respectively.  
Studies of OAS1 isoform specific expression are limited to detecting only p46 due 
to commercially available antibody. Investigating the expression of p48 required us to 
develop a p48 specific antibody. As stated in the materials and methods, the unique 
synthetic peptide at the C-term end of p48, a result of splice site polymorphism (Fig. 2D) 
was used to generate a polyclonal antibody in a rabbit. Figure 7 shows the purified IgG 
fraction from the serum of the immunized rabbit which was used to demonstrate antibody 
reactivity and specificity using synthetic peptide. The purified IgG fraction was tested 
amongst whole protein extracts from cell lines that are either null (HEK293T) or express 
OAS1 isoforms p48 and p46 (PCa cell lines DU145, LNCaP and PC3) 108 (Fig. 7).  The 
genomic DNA from the prostate cancer cell lines was first genotyped for rs10774671.  
The following genotype for rs10774671 was observed: LNCaP: GG, DU145 and PC3: 
GA.  Consistent with our earlier studies, OAS1 protein was not expressed in LNCaP cells 
(Fig. 7). 108  The expression of OAS1 p46 and p48 was detected in DU145 and PC3 cells 
(Fig. 7).  Pre-incubation of the p48 antibody with the p48 synthetic peptide used to 
generate the antibody resulted loss of reactivity of the p48 antibody on the western blot 





Figure 7. OAS1 expression profile in prostate cancer. OAS1 protein expression in prostate cancer cell lines 
DU145, LNCaP, PC3 and normal control HEK293T with western blot analysis. Whole cell lysates were 
used for the analysis of protein expression of OAS1 isoforms (p46) & (p48) in prostate cancer cell lines. 
GAPDH was used as loading control. The p48 peptide was included in western blot analysis against p46 
and p48 protein expression. Pre-incubation of the p48 antibody with the p48 synthetic peptide (p48ptd) was 
used to confirm specificity of the p48 antibody. 
 
4.2.1 Expression of 2-5OAS1 Isoforms in Prostate Tissue 
The OAS1 p46 and p48 expression was detected on prostate cancer tissue 
microarrays, displayed in Figure 8. The expression was analyzed in 41 prostate cancers 
(mean age 70+7.9, Grade I: n= 9, Grade II: n=14, Grade III: n=18), 6 BPH (mean age 
73+4.6) and 8 normal (mean age 53.35+16.5) prostate core biopsies (1.5mm) in duplicate 
(BC19014, BC19111 and T192, US BioMax, Inc., Rockville, MD).  BPH and normal 
cores were collectively considered as normal (n=14). The staining intensity was rated 
from 1 for below the level of detection to 4 for strongest expression by two independent 
observers. The observers were only informed about the antibody being scored. The 
correlation coefficient between the assessment of OAS1 staining by two independent 
observers was r = 0.92- 0.96.  
OAS1 p46 expression was low to undetectable in majority of normal (low 2/ 14: 
14%, undetectable 12/14: 86%) and Grade I (low 4/9: 44%, undetectable 56%) (Fig. 8a 
and 8b).  The expression levels were not different between normal and grade I (Fig. 8a).  
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The p46 expression increased dramatically in grade II and grade III (p<0.001 as 
compared to control) (Fig. 8a).  Conversely, the expression of OAS 1 p48 isoform was 
high in the normal and decreased significantly in prostate cancer (Fig. 8a and Fig. 8b).  
The expression of both the isoforms was both cytoplasmic and nuclear (Fig. 8a).  The 
expression of OAS1 isoform and the IHC results were in direct correlation with the 
genotyping data (Table 2 and Fig. 8a and 8b). 
 
Figure 8. Immuno-histochemical analysis and expression profile of OAS1 p46 and p48 in prostate cancer 
tissue. A: Representative OAS1 p46 and p48 isoform specific expression by immuno-histochemistry on 
normal prostate and prostate cancer tissue microarray. Representative images from Normal, Grade II and 
Grade IV are shown. The OAS1 p46 and p58 expression is indicated by brown staining. The blue staining 
(Hematoxylin) represents the nuclei.   Each panel is 400x. B: OAS1 expression profile in prostate tissue. 
Semi-quantitative analysis of OAS1 p46 and p48 expression (staining intensity from 0-3) in normal 
prostate (including BPH), and prostate cancer (grade I-III).  The Kruskal-Wallis statistics H indicated 
significant differences within group (P <0.001 for p46 and P <0.0022 for p48).  The post-hoc Mann and 
Whitney test was used to determine statistical differences between groups as compared to respective 
staining in normal: NS: non-specific, * P<0.05, **P<0.01*** P<0.001.  Data is represented as Box and 
Whisker plots. 
 
4.3 DbGaP Analysis Outline of OAS1 
In case-control studies, evaluating association between a candidate allele and a 
disease, allele-based tests and genotype-based tests are equivalent when HWE holds. 141 
Alleles that did not uphold HWE within the OAS 1 locus and Chromosome 12 from 
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either the MEC or CGEMS datasets were excluded from our analysis. Once HWE was 
confirmed we analyzed the distribution of allele case/control analysis for individual SNPs 
on the OAS1 gene region and on chromosome 12. A subsequent meta-analysis was 
conducted on the SNPs present amongst both DbGaP datasets (MEC and CGEMS). The 
pipeline of procedures used to analyze the GWAS datasets is shown in Figure 9.  
 
Figure 9. GWAS analysis pipeline. Outlining the computational analysis procedure that generated PCa 
disease association results, and Meta-Analysis between MEC and CGEMS datasets.  
4.3.1 GWAS Illumina Platforms  
To advance from the candidate gene approach of OAS1 exon F we expanded our 
investigation to a GWAS of the MEC and CGEMS datasets. We focused on the African-
American cohort within the MEC dataset (n=2,841) and the CGEMS European dataset 
(n=2,329). Our observations of the dataset platforms from the University of California 
Santa Cruz (UCSC) Genome browser, shown in Figure 10, exhibited that some OAS1 
exon F SNPs within our haplotype were not genotyped on all the Illunima Platforms 
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provided by the datasets. 142-143 The MEC African-American Cohort contained the 
genotypes for SNPs rs10774671, rs1131476, rs11836381, and rs2660 and the CGEMS 
dataset contained the genotype only for rs1131476, within OAS1 exon F gene region. 
Therefore, an expansion from the OAS1 candidate gene health disparities study could be 
carried out only on SNP rs1131476 as it is common to both MEC and CGEMS datasets. 
We then sought to increase our analysis of SNPs common to both datasets found on 
chromosome 12 for health disparity investigation. 
 
Figure 10. UCSC genome browser representation of OAS1. UCSC Genome Browser image of SNPs 
presented on the platforms on OAS1of from the following Genome Wide Association Studies: Multiethnic 
Genome-wide Scan of Prostate Cancer- Japanese and Latino cohort - Platform: Illumina 660W-Q- 
(rs1131476), African-American Cohort-Platform: Illumina1M-Duo- (rs10774671, rs1131476, rs11836381, 
and rs2660)  and the Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer Genome-Wide 










4.3.2 MEC and CGEMS Hardy Weinberg Equilibrium Test  
A crucial step in maintaining quality control of GWAS datasets, is determining 
the HWE status of the subject’s genotype. When studying multiple ethnicities within the 
same study it is essential to test for HWE within each group separately. 144 Therefore, we 
performed HWE tests on the SNPs genotyped on Chromosome 12 of the MEC and 
CGEMS datasets separately, demonstrated in Table 5. When HWE is not satisfied allele-
based test are invalid. 141 Upon our analysis we removed any SNPs that displayed 
significant deviation from HWE. HWE analysis returned 55,918 SNPs from the MEC and 
14,884 SNPs from CGEM datasets. We determined that all the SNPs within the MEC and 
CGEMS datasets that deviated from HWE were products of potential genotyping errors 
and population stratification which would skew our case-control analysis 144-145 therefore, 
a combined total of ~2,000 SNPs whose HWE p < 0.05 were excluded from further 
analysis procedures. The datasets were additionally pruned down exclusively to SNPs 
that were genotyped on both Illumina platforms from the MEC and CGEMS datasets for 




Table 5. SNPs in HWE Common to MEC and CGEMS Datasets * 
 
*Total SNPs from Chromosome 12 tested during HWE analysis are excluded from this image. This is only 
representative of the SNPs were that underwent case-control and meta-analysis.  
 
4.3.3 MEC and CGEMS Case-Control and Meta-Analysis 
 
In Table 6, we combined the African-American Cohort from the MEC dataset 
with individuals of European ancestry from the CGEMS dataset and performed a meta-
analysis on a total of 5,170 individuals. We extracted 12,536 SNPs in HWE that were 
common to both datasets. The SNPs genotyped in OAS1 gene region (highlighted in 
yellow, Table 6a and 6b) revealed no significant associations with PCa risk or protection. 
Of the 12,536 SNPs we proceeded to filter SNPs that were associated with PCa risk (P-
value < 0.05 and OR >1) and associated with PCa protectiveness (P-value < 0.05 and OR 
< 1). The SNPs preceding the OAS1 subset with P-values < 0.05 and OR’s > 1 are 
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associated with PCa risk (rs11066226, rs2301757, rs10506874 and rs11066209). The 
SNPs precluding the OAS1 subset displaying a P-value < 0.05 and ORs < 1 are 
associated with PCa protectiveness (rs969845, rs10506151, rs4129598, rs2710697) 
(Table 6). 




We then wanted to analyze the stratification between ethnicities with health 
disparities between the risk and protective associated SNPs highlighted in our meta-
analysis, demonstrated in Table 7. Our overall observation revealed that significant risk 
or protectiveness was influenced most by the CGEMS cohort of European ancestry 
(Table 7B). A significant example of the difference in severity of risk association can be 
seen with SNP rs10506874 (CGEMS, P = 0.000849 OR=1.36 vs. MEC-AfAm, P = 
0.3504 OR=1.166). However, when looking at the SNPs deemed to be the most 
protective on Chromosome 12 common to both ethnic groups even the most protective 
SNP among African Americans (rs10506151, Table 7A) is not as potent in comparison to 
the European cohort (CGEMS, P = 0.009773 OR= 0.8093 vs. MEC-AfAm, P = 0.02559 
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OR= 0.7379). Lastly, when separated we still do not observe any significant association 
of OAS1 with PCa risk or protectiveness (yellow highlighted region, Table 7A and 7B). 








5.1 OAS1 Candidate Gene Study 
The SNPs within our candidate gene approach are all located in the 7th exon of 
OAS1 isoforms I (p46) and III (p48) and are characterized in a variety of diseases 
separately but when studied together remain elusive in PCa risk and progression. Given 
the central role of OAS1 in activating the well-known prostate cancer tumor suppressor 
RNaseL, 10 OAS1 is a viable susceptibility gene for prostate cancer risk as well. Overall, 
genetic variation caused by SNPs are of interest due to their ability to predict risk, 
classify tumors, and identify therapeutic targets required to understand the genetic 
changes underlying cancer initiation and progression. Thus far, this is the first account of 
these 2-5 OAS1 SNPs in association with PCa. Our results are also significant in context 
of the observations that no somatic mutations have been discovered in OAS1 (cBIO 
Portal prostate adenocarcinoma datasets). 146-147 
Earlier studies suggested that the four SNPs rs1131476, rs1051042, rs2660 and 
the splice site polymorphism rs10774671 are in linkage disequilibrium 12 The data from 
two publicly available studies (Perlegen and SNP500) also suggested that these 4 SNPs 
were in linkage disequilibrium, at least in the normal population. 109, 148  However, 
stratification of the SNP data based on race suggested linkage disequilibrium decay 
between rs10774671 and the rest of the SNPs rs1131476, rs1051042, and rs2660 in these 
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studies.  The frequency of rs10774671 is essentially similar between Caucasians and 
African Americans but the decay in the remaining haplotype block (rs1131476, 
rs1051042, rs2660) in African Americans suggest that these polymorphisms may be 
functionally relevant between ethnicities. 
5.1.1 OAS1 Candidate Gene Study rs10774671 
By far the most important observation that came out of this study is the strong 
association of the splice site polymorphism with prostate cancer irrespective of race. The 
SNP rs10774671 GG genotype (isoform p46) has a strong presence among those with 
PCa that was also confirmed by its strong expression in prostate cancer tissue specimens. 
Conversely, the rs10774671 AA genotype is strongly associated with the healthy subjects 
suggesting that this genotype is protective against prostate cancer (Table 2 and Figure 
6A).  The TMA results further confirmed high p48 expression in normal prostate 
specimens as opposed to low expression in prostate cancer tissue (Fig. 8). The AA and 
GG genotypes are equally distributed in all healthy subjects; however, frequencies appear 
to differ following stratification by race.  The higher frequency of GG genotype in 
African Americans as compared to Caucasians suggests that African-American normal 
subjects may have increased susceptibility to PCa and as such this genotype may 
represent a risk allele for PCa. In addition, the absence of the GA genotype amongst our 
cases could be indicative of its role as a protective genotype. Long term follow-up studies 
of normal subjects with GG and GA genotypes can be performed to assess their risk of 




In a study of Danish families, the strongest association of OAS1 enzyme activity 
was associated with rs10774671 GG genotype (earlier known as hCV25i67433) in the 
p46 isoform.12  The genotyping of 12 markers across and flanking the OAS gene cluster 
on chromosome 12 suggest that the highest enzyme activity is associated with SNP 
markers in OAS1, specifically, the rs10774671 GG genotype. 12  It is therefore counter-
intuitive that a strong association of the AA genotype (p48) with low enzyme activity is 
associated with normal subjects.  It is likely that other factors, environmental/ biological 
may modify the p46 activity resulting in the strong association with cancer as observed in 
our studies. 
5.1.2 OAS1 Candidate Gene Study Haplotype 
As stated earlier, the fours SNPs are in complete linkage disequilibrium, at least 
in the Caucasian population (Danish Study) . 12  Only two haplotypes: GGGG (frequency 
0.32) and AACA (frequency 0.68) were reported in the study population. 12 The GACA 
haplotype was rare and found in only one parent (and both children). Our results also 
suggest that the AACA haplotype is the majority haplotype in the general population 
(high frequency contributed by the Caucasian subjects) but occurs at lower frequency in 
the African-American population as compared to GACA (Fig. 6C). The AACA haplotype 
also associates strongly with normal subjects and appears to be protective for PCa (Table 
4). The GACA genotype, possibly driven by the GG genotype of rs10774671 strongly 
associates with prostate cancer.  It is likely that the ACA haplotype between the last three 
SNPs (rs1131476, rs1051042 and rs2660) have no association (Table 3) but collectively 
all four genotypes as a haplotype block associates significantly with prostate cancer.  The 
51 
 
GACA haplotype, though detected rarely in the Danish study, is observed at much higher 
frequency (10%) in our study (normal Caucasian). These differences could reflect 
admixture with other races other than African Americans since this haplotype is rarely 
observed amongst the African-American group in our study.  
5.2 GWAS of OAS1 Gene Region 12q24 
When looking at the OAS1 gene region we observed that none of the SNPs fell 
into the parameters of significant disease association (P < 0.05 and OR >/< 1). It was also 
challenging to build a comprehensive GWAS health disparity analysis of the OAS1 exon 
F gene region considering the SNPs that were of our primary focus in the candidate gene 
study were not genotyped among both cohorts.  Rs1131476 which was the only SNP in 
the OAS1 exon F gene region and common to both cohorts did not exhibit any 
association with PCa risk or protectiveness in our candidate gene study and was 
consistent when analyzed in the GWAS datasets. Interestingly, rs1077461, which was 
genotyped in the MEC African-American cohort, displayed no significant PCa 
association when examined in that dataset (P=0.5129, OR=0.9646).  
5.2.1 GWAS Risk Genotypes Found on CHR 12  
PLINK meta-analysis and association testing presented rs11066226, rs2301757, 
rs10506874 and rs11066209 with peripheral association to PCa risk. Published 
reporting’s of GWAS results typically mention SNPs that reach genome-wide 
significance (p of association ≤ 10-7); however the SNPs identified in this study whose P-
values peaked at p ≤ 10-3 – 10-4  may indicate some level of significance (Table 5 and 
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Table 6b) belonging to a gene of interest sufficient enough to be addressed within a 
candidate gene study. 149  
Three of the four SNPs associated with PCa risk were common variants within 
HECT domain E3 ubiquitin protein ligase 4 (HECTD4) [rs11066226 (T > C - Intron), 
rs2301757 (T > G - Synonymous), rs11066209 (A > G - Intron)]. HECTD4 (HECT 
domain E3 ubiquitin protein ligase 4), is an E3 ligases that accepts ubiquitin from an E2 
ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the 
ubiquitin moiety to target substrates. 150 The clinical function of HECTD4 has not been 
elucidated but studies have shown that HECTD4 variants exhibit protective effects in 
developing diabetes in males. 150-151 The relationship of HECTD4’s variants with diabetes 
association could link it to the role OAS1’s variants that contribute to diabetes 
susceptibility making them linked genes. This contributes to the concept that complex 
traits or complex diseases such as prostate cancer can be influenced by low penetrant 
variants found on multiple genes, (HECTD4 and OAS1) that can also be influenced and 
linked to an individual’s susceptibility to other diseases. 152 The only way to confirm 
these associations is to design GWAS studies with an inventory of the patients’ overall 
history of health. Additionally, variants of HECTD4 have also been associated with lung 
adenocarcinoma among Chinese subjects. 153  
5.2.2 GWAS Protective Genotypes Found on CHR 12 
PLINK meta-analysis and association testing presented rs969845, rs10506151, 
rs4129598, and rs2710697 with peripheral association to PCa risk in the African-
American cohort and significantly amongst the Caucasian cohort (Table 5a and 5b). This 
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hypothesis free analysis of chromosome 12 between the comparable protective markers 
among the differing cohorts of ethnicity could be telling of the decreased incidence and 







Alternative splicing gives rise to functional diversity of proteins, alters their 
biological activity, and impacts disease pathogenesis.  For example, inherited germ line 
mutation in exon 18 of BRCA1, associated with pre-disposition of breast and ovarian 
cancer disrupts an exonic splice enhancer, skipping exon 18. 154  Moreover, polymorphic 
(CAG)n and (GGN)n regions within the androgen receptor gene are associated with the 
risk of developing prostate cancer. 155 Thus, the association of splice site polymorphism 
in OAS1 can have major implications within the Interferon regulated RNASEL pathway.   
We demonstrated earlier that the rs2660 SNP was associated with prostate 
cancer.108  In the present study; however, the association was not statistically significant. 
This result is not unexpected, especially for an allele that is strongly associated with race 
(extremely low frequency of rs2660 GG genotype in African-American Men).108  The 
contrasting result could reflect that the sample population under study and interaction 
with external (environmental) and internal factors (cross-talk between pathways) that 
may cooperate with rs2660.  These results led us to propose that rs2660 may not be the 
causal variant and that there could be other polymorphisms that are biologically relevant, 
or alternatively rs2660 may be in linkage disequilibrium or LD decay with another 
variant that associates with prostate cancer risk. This may explain the discrepancy
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associated with rs2660 and prostate cancer, but more importantly, supports fine mapping 
of the haplotype to understand the genetic variations within this locus.  
Interpretation of association and outcomes of specific OAS1 isoforms through the 
analysis of SNPs and haplotypes from our population-based studies yielded significant 
results. Our findings suggest that isoform 1 of OAS1 is associated with PCa risk whereas 
isoform 3 is associated with healthy outcomes. Although, isoform 1 has been considered 
the most enzymatically active of the OAS1 gene paralogues thus assuming it’s protective 
role as an ISG, but a splicing SNP rs10774671, may lead to an unknown functional 
dichotomy that is associated with cancer risk. 
 Carrying over our evidence from the candidate gene study which distinguished 
(genotypically and biologically) OAS1 isoform 1 association with PCa risk and OAS1 
isoform 3 with protectiveness, we sought to employ GWAS to our current knowledge of 
OAS1 and PCa, considering the significant contributions GWAS has made in the last 10 
years. The high-throughput genetic analysis offered by GWAS has proven highly 
beneficial in understanding diseases with multiple genetic influences that are complex in 
their etiology, such as PCa. 156 However, when increasing our sample size and 
implementing multiple GWAS datasets that utilized different genotyping platforms we 
experienced a loss of significance in our analysis of OAS1 SNPs in association to PCa, 
specifically with rs10774671. This is not a unique issue considering many previous 
candidate genes identified in complex diseases by hypothesis driven approaches are not 
always replicated by GWAS at a genome wide significance level.157 Additionally, when 
transitioning to a GWAS increased sample sizing requires a need for more stringent 
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statistical power techniques. 149 We strongly believe that our hypothesis driven candidate 
gene approach verified with biological significance, rather than the discovery based 
GWAS approach provides a foundational understanding of the functional role of SNPs in 
PCa. Furthermore, our study established that a lower sample size is necessary for testing 
a smaller number of common SNPs. This same concept has been demonstrated through 
an investigation conducted by Eun Pyo Hong et al. where they established the effects of 
sample size on the statistical power of case-control and GWAS studies. 158 They provide 
evidence that an effective sample size is defined by the minimum number of samples 
required to achieve adequate statistical power (e.g., 80% power).158 
 Because GWAS is hypothesis-free, it has become a useful tool in 
understanding unknown aspects of many common human diseases through the 
examination of hundreds of thousands of genetic markers across the human genome. 
When we looked outside of the OAS1 gene region we found disease association among 
other variants located in other gene regions, suggesting OAS1 is implicated with gene-
gene interactions. These gene interactions merit a follow up study that can be designed 
carefully to create various data points for a future multifactorial GWAS. Studies of this 
magnitude require foresight in their design. A future study that considers the patient’s 
ethnicity and admixture, while including their full health history, with specifically 
designed sequencing platforms, would make the ideal GWAS that utilizes various data 






1. Cheon, H.; Borden, E. C.; Stark, G. R., Interferons and their stimulated genes in the 
tumor microenvironment. Semin Oncol 2014, 41 (2), 156-73. 
2. Fish, I.; Boissinot, S., Functional evolution of the OAS1 viral sensor: Insights from old 
world primates. Infect Genet Evol 2016, 44, 341-350. 
3. Hovnanian, A.; Rebouillat, D.; Mattei, M. G.; Levy, E. R.; Marie, I.; Monaco, A. P.; 
Hovanessian, A. G., The human 2',5'-oligoadenylate synthetase locus is composed 
of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, 
and 40-kDa forms. Genomics 1998, 52 (3), 267-77. 
4. Vachon, V. K.; Calderon, B. M.; Conn, G. L., A novel RNA molecular signature for 
activation of 2'-5' oligoadenylate synthetase-1. Nucleic Acids Res 2015, 43 (1), 
544-52. 
5. Nilsen, T. W.; Maroney, P. A.; Baglioni, C., Double-stranded RNA causes synthesis of 
2',5'-oligo(A) and degradation of messenger RNA in interferon-treated cells. J 
Biol Chem 1981, 256 (15), 7806-11. 
6. Yaffe, A.; Schwarz, Y.; Hacohen, D.; Kinar, Y.; Nir, U.; Salzberg, S., Inhibition of 2-
5A synthetase expression by antisense RNA interferes with interferon-mediated 
antiviral and antiproliferative effects and induces anchorage-independent cell 
growth. Cell Growth Differ 1996, 7 (8), 969-78. 
7. Rennert, H.; Zeigler-Johnson, C. M.; Addya, K.; Finley, M. J.; Walker, A. H.; 
Spangler, E.; Leonard, D. G.; Wein, A.; Malkowicz, S. B.; Rebbeck, T. R., 
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and 
MSR1 with prostate cancer severity in European American and African American 
men. Cancer Epidemiol Biomarkers Prev 2005, 14 (4), 949-57. 
8. Wang, L.; McDonnell, S. K.; Elkins, D. A.; Slager, S. L.; Christensen, E.; Marks, A. 
F.; Cunningham, J. M.; Peterson, B. J.; Jacobsen, S. J.; Cerhan, J. R.; Blute, M. 
L.; Schaid, D. J.; Thibodeau, S. N., Analysis of the RNASEL gene in familial and 





9. Malathi, K.; Paranjape, J. M.; Ganapathi, R.; Silverman, R. H., HPC1/RNASEL 
mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, 
topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing 
ligand. Cancer Res 2004, 64 (24), 9144-51.10. Silverman, R. H., Viral encounters 
with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral 
response. Journal of virology 2007, 81 (23), 12720-9. 
11. Salzberg, S.; Hyman, T.; Turm, H.; Kinar, Y.; Schwartz, Y.; Nir, U.; Lejbkowicz, F.; 
Huberman, E., Ectopic expression of 2-5A synthetase in myeloid cells induces 
growth arrest and facilitates the appearance of a myeloid differentiation marker. 
Cancer Res 1997, 57 (13), 2732-40. 
12. Bonnevie-Nielsen, V.; Field, L. L.; Lu, S.; Zheng, D. J.; Li, M.; Martensen, P. M.; 
Nielsen, T. B.; Beck-Nielsen, H.; Lau, Y. L.; Pociot, F., Variation in antiviral 
2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-
nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum 
Genet 2005, 76 (4), 623-33. 
13. Mullan, P. B.; Hosey, A. M.; Buckley, N. E.; Quinn, J. E.; Kennedy, R. D.; Johnston, 
P. G.; Harkin, D. P., The 2,5 oligoadenylate synthetase/RNaseL pathway is a 
novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene 
2005, 24 (35), 5492-501. 
14. Austin, B. A.; James, C.; Silverman, R. H.; Carr, D. J., Critical role for the 
oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute 
ocular herpes simplex virus type 1 infection. J Immunol 2005, 175 (2), 1100-6. 
15. Lim, J. K.; Lisco, A.; McDermott, D. H.; Huynh, L.; Ward, J. M.; Johnson, B.; 
Johnson, H.; Pape, J.; Foster, G. A.; Krysztof, D.; Follmann, D.; Stramer, S. L.; 
Margolis, L. B.; Murphy, P. M., Genetic variation in OAS1 is a risk factor for 
initial infection with West Nile virus in man. PLoS Pathog 2009, 5 (2), e1000321. 
16. Min, J. Y.; Krug, R. M., The primary function of RNA binding by the influenza A 
virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo (A) synthetase/RNase 
L pathway. Proc Natl Acad Sci U S A 2006, 103 (18), 7100-5. 
17. Fedetz, M.; Matesanz, F.; Caro-Maldonado, A.; Fernandez, O.; Tamayo, J. A.; 
Guerrero, M.; Delgado, C.; Lopez-Guerrero, J. A.; Alcina, A., OAS1 gene 
haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006, 68 
(5), 446-9. 
18. O'Brien, M.; Lonergan, R.; Costelloe, L.; O'Rourke, K.; Fletcher, J. M.; Kinsella, K.; 
Sweeney, C.; Antonelli, G.; Mills, K. H.; O'Farrelly, C.; Hutchinson, M.; Tubridy, 
N., OAS1: a multiple sclerosis susceptibility gene that influences disease severity. 




19. Bonnevie-Nielsen, V.; Martensen, P. M.; Justesen, J.; Kyvik, K. O.; Kristensen, B.; 
Levin, K.; Beck-Nielsen, H.; Worsaa, A.; Dyrberg, T., The antiviral 2',5'-
oligoadenylate synthetase is persistently activated in type 1 diabetes. Clin 
Immunol 2000, 96 (1), 11-8. 
20. Field, L. L.; Bonnevie-Nielsen, V.; Pociot, F.; Lu, S.; Nielsen, T. B.; Beck-Nielsen, 
H., OAS1 splice site polymorphism controlling antiviral enzyme activity 
influences susceptibility to type 1 diabetes. Diabetes 2005, 54 (5), 1588-91. 
21. Karinen, S.; Saarinen, S.; Lehtonen, R.; Rastas, P.; Vahteristo, P.; Aaltonen, L. A.; 
Hautaniemi, S., Rule-based induction method for haplotype comparison and 
identification of candidate disease loci. Genome Med 2012, 4 (3), 21. 
22. McNeal, J. E., Normal histology of the prostate. Am J Surg Pathol 1988, 12 (8), 619-
33. 
23. Myers, R. P., Structure of the adult prostate from a clinician's standpoint. Clin Anat 
2000, 13 (3), 214-5. 
24. Holland-Frei Cancer Medicine. 6th edition. BC Decker: 2003. 
25. Abate-Shen, C.; Shen, M. M., Molecular genetics of prostate cancer. Genes Dev 
2000, 14 (19), 2410-34. 
26. Berges, R. R.; Vukanovic, J.; Epstein, J. I.; CarMichel, M.; Cisek, L.; Johnson, D. E.; 
Veltri, R. W.; Walsh, P. C.; Isaacs, J. T., Implication of cell kinetic changes 
during the progression of human prostatic cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 1995, 1 (5), 
473-80. 
27. Sfanos, K. S.; De Marzo, A. M., Prostate cancer and inflammation: the evidence. 
Histopathology 2012, 60 (1), 199-215. 
28. Reid-Pitts, W., Jr., Prostatic intraepithelial neoplasia and putative precursor lesions of 
prostate cancer: a clinical perspective. BJU international 2001, 88 (9), 985-6. 
29. Woenckhaus, J.; Fenic, I., Proliferative inflammatory atrophy: a background lesion of 
prostate cancer? Andrologia 2008, 40 (2), 134-7. 
30. Herget, K. A.; Patel, D. P.; Hanson, H. A.; Sweeney, C.; Lowrance, W. T., Recent 
decline in prostate cancer incidence in the United States, by age, stage, and 
Gleason score. Cancer Med 2016, 5 (1), 136-41. 
31. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer Statistics, 2017. CA Cancer J Clin 




32. Loukola, A.; Chadha, M.; Penn, S. G.; Rank, D.; Conti, D. V.; Thompson, D.; Cicek, 
M.; Love, B.; Bivolarevic, V.; Yang, Q.; Jiang, Y.; Hanzel, D. K.; Dains, K.; 
Paris, P. L.; Casey, G.; Witte, J. S., Comprehensive evaluation of the association 
between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and 
SRD5A2. Eur J Hum Genet 2004, 12 (4), 321-32. 
33. Hayes, R. B.; Pottern, L. M.; Strickler, H.; Rabkin, C.; Pope, V.; Swanson, G. M.; 
Greenberg, R. S.; Schoenberg, J. B.; Liff, J.; Schwartz, A. G.; Hoover, R. N.; 
Fraumeni, J. F., Jr., Sexual behaviour, STDs and risks for prostate cancer. Br J 
Cancer 2000, 82 (3), 718-25. 
34. Nelson, W. G.; DeWeese, T. L.; DeMarzo, A. M., The diet, prostate inflammation, 
and the development of prostate cancer. Cancer Metastasis Rev 2002, 21 (1), 3-
16. 
35. Pomerantz, M. M.; Freedman, M. L., The genetics of cancer risk. Cancer J 2011, 17 
(6), 416-22. 
36. Alberti, C., Hereditary/familial versus sporadic prostate cancer: few indisputable 
genetic differences and many similar clinicopathological features. Eur Rev Med 
Pharmacol Sci 14 (1), 31-41. 
37. Division of Cancer Prevention and Control, N. C. f. C. D. P. a. H. P., Prostate Cancer 
Rates by Race and Ethnicity. Prostate Cancer Incidence Rates* by Race and 
Ethnicity, U.S., 1999–2008 2012. 
38. Yeager, M.; Orr, N.; Hayes, R. B.; Jacobs, K. B.; Kraft, P.; Wacholder, S.; 
Minichiello, M. J.; Fearnhead, P.; Yu, K.; Chatterjee, N.; Wang, Z.; Welch, R.; 
Staats, B. J.; Calle, E. E.; Feigelson, H. S.; Thun, M. J.; Rodriguez, C.; Albanes, 
D.; Virtamo, J.; Weinstein, S.; Schumacher, F. R.; Giovannucci, E.; Willett, W. 
C.; Cancel-Tassin, G.; Cussenot, O.; Valeri, A.; Andriole, G. L.; Gelmann, E. P.; 
Tucker, M.; Gerhard, D. S.; Fraumeni, J. F., Jr.; Hoover, R.; Hunter, D. J.; 
Chanock, S. J.; Thomas, G., Genome-wide association study of prostate cancer 
identifies a second risk locus at 8q24. Nat Genet 2007, 39 (5), 645-9. 
39. Esfahani, M.; Ataei, N.; Panjehpour, M., Biomarkers for Evaluation of Prostate 
Cancer Prognosis. Asian Pacific journal of cancer prevention : APJCP 2015, 16 
(7), 2601-2611. 
40. He, M. L.; Chen, Y.; Chen, Q.; He, Y.; Zhao, J.; Wang, J.; Yang, H.; Kung, H. F., 
Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a 
whole-exome sequencing study. American journal of cancer research 2011, 1 (4), 
562-73. 
41. Li, J.; Fan, Q. H.; Fan, X. S.; Zhou, W.; Qiu, Y.; Qiu, L., [EZH2 expression in human 
prostate cancer and its clinicopathologic significance]. Zhonghua Nan Ke Xue 
2010, 16 (2), 123-8. 
61 
 
42. Li, D.; Kumaraswamy, E.; Harlan-Williams, L. M.; Jensen, R. A., The role of 
BRCA1 and BRCA2 in prostate cancer. Front Biosci (Landmark Ed) 2013, 18, 
1445-59. 
43. Eeles, R.; Goh, C.; Castro, E.; Bancroft, E.; Guy, M.; Al Olama, A. A.; Easton, D.; 
Kote-Jarai, Z., The genetic epidemiology of prostate cancer and its clinical 
implications. Nat Rev Urol 2014, 11 (1), 18-31. 
44. Ahsan, M.; Ek, W. E.; Rask-Andersen, M.; Karlsson, T.; Lind-Thomsen, A.; Enroth, 
S.; Gyllensten, U.; Johansson, A., The relative contribution of DNA methylation 
and genetic variants on protein biomarkers for human diseases. PLoS Genet 2017, 
13 (9), e1007005. 
45. Begum, F.; Ghosh, D.; Tseng, G. C.; Feingold, E., Comprehensive literature review 
and statistical considerations for GWAS meta-analysis. Nucleic Acids Res 2012, 
40 (9), 3777-84. 
46. Nakagawa, H.; Akamatsu, S.; Takata, R., [Genome-wide association study(GWAS) 
and genetic risk of prostate cancer]. Nihon Rinsho 2016, 74 (1), 34-9. 
47. Shridhar Ghagane, R. B. N., Basappa Basawanneppa Kaliwal, Murigendra B 
Hiremath, Single Nucleotide Polymorphisms: A New Paradigm in Predicting the 
Risk of Prostate Cancer. Cell & Developmental Biology 2016, 5 (1). 
48. Okobia, M. N.; Zmuda, J. M.; Ferrell, R. E.; Patrick, A. L.; Bunker, C. H., 
Chromosome 8q24 variants are associated with prostate cancer risk in a high risk 
population of African ancestry. Prostate 2011, 71 (10), 1054-63. 
49. Oh, J. J.; Lee, S. J.; Hwang, J. Y.; Kim, D.; Lee, S. E.; Hong, S. K.; Ho, J. N.; Yoon, 
S.; Sung, J.; Kim, W. J.; Byun, S. S., Exome-based genome-wide association 
study and risk assessment using genetic risk score to prostate cancer in the Korean 
population. Oncotarget 2017, 8 (27), 43934-43943. 
50. Hoffmann, T. J.; Passarelli, M. N.; Graff, R. E.; Emami, N. C.; Sakoda, L. C.; 
Jorgenson, E.; Habel, L. A.; Shan, J.; Ranatunga, D. K.; Quesenberry, C. P.; 
Chao, C. R.; Ghai, N. R.; Aaronson, D.; Presti, J.; Nordstrom, T.; Wang, Z.; 
Berndt, S. I.; Chanock, S. J.; Mosley, J. D.; Klein, R. J.; Middha, M.; Lilja, H.; 
Melander, O.; Kvale, M. N.; Kwok, P. Y.; Schaefer, C.; Risch, N.; Van Den 
Eeden, S. K.; Witte, J. S., Genome-wide association study of prostate-specific 
antigen levels identifies novel loci independent of prostate cancer. Nature 
communications 2017, 8, 14248. 
51. Whitington, T.; Gao, P.; Song, W.; Ross-Adams, H.; Lamb, A. D.; Yang, Y.; Svezia, 
I.; Klevebring, D.; Mills, I. G.; Karlsson, R.; Halim, S.; Dunning, M. J.; Egevad, 
L.; Warren, A. Y.; Neal, D. E.; Gronberg, H.; Lindberg, J.; Wei, G. H.; Wiklund, 
F., Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat 
Genet 2016, 48 (4), 387-97. 
62 
 
52. Jiao, Y.; Wang, L.; Gu, X.; Tao, S.; Tian, L.; Na, R.; Chen, Z.; Kang, J.; Zheng, S. L.; 
Xu, J.; Sun, J.; Qi, J., LILRA3 is associated with benign prostatic hyperplasia risk 
in a Chinese Population. International journal of molecular sciences 2013, 14 (5), 
8832-40. 
53. Weng, P. H.; Huang, Y. L.; Page, J. H.; Chen, J. H.; Xu, J.; Koutros, S.; Berndt, S.; 
Chanock, S.; Yeager, M.; Witte, J. S.; Eeles, R. A.; Easton, D. F.; Neal, D. E.; 
Donovan, J.; Hamdy, F. C.; Muir, K. R.; Giles, G.; Severi, G.; Smith, J. R.; 
Balistreri, C. R.; Shui, I. M.; Chen, Y. C., Polymorphisms of an innate immune 
gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review 
and meta-analysis. PLoS One 2014, 9 (10), e110569. 
54. Breyer, J. P.; McReynolds, K. M.; Yaspan, B. L.; Bradley, K. M.; Dupont, W. D.; 
Smith, J. R., Genetic variants and prostate cancer risk: candidate replication and 
exploration of viral restriction genes. Cancer Epidemiol Biomarkers Prev 2009, 
18 (7), 2137-44. 
55. Wu, M. C.; Kraft, P.; Epstein, M. P.; Taylor, D. M.; Chanock, S. J.; Hunter, D. J.; 
Lin, X., Powerful SNP-set analysis for case-control genome-wide association 
studies. Am J Hum Genet 2010, 86 (6), 929-42. 
56. International HapMap, C., The International HapMap Project. Nature 2003, 426 
(6968), 789-96. 
57. Ahn, T. J.; Park, K.; Son, D. S.; Huh, N.; Oh, S.; Bae, T.; Park, J. S.; Lee, J. H.; Rho, 
K.; Kim, S.; Park, T.; Lee, K., Selecting SNPs for pharmacogenomic association 
study. International journal of data mining and bioinformatics 2012, 6 (5), 521-
34. 
58. Zhang, X.; Zhang, W.; Saraf, S. L.; Nouraie, M.; Han, J.; Gowhari, M.; Hassan, J.; 
Miasnikova, G.; Sergueeva, A.; Nekhai, S.; Kittles, R.; Machado, R. F.; Garcia, J. 
G.; Gladwin, M. T.; Steinberg, M. H.; Sebastiani, P.; McClain, D. A.; Gordeuk, 
V. R., Genetic polymorphism of APOB is associated with diabetes mellitus in 
sickle cell disease. Human genetics 2015, 134 (8), 895-904. 
59. Jorde, L. B., Linkage disequilibrium and the search for complex disease genes. 
Genome research 2000, 10 (10), 1435-44. 
60. Netea-Maier, R. T.; Smit, J. W. A.; Netea, M. G., Metabolic changes in tumor cells 
and tumor-associated macrophages: A mutual relationship. Cancer Lett 2018, 
413, 102-109. 
61. De Marzo, A. M.; Marchi, V. L.; Epstein, J. I.; Nelson, W. G., Proliferative 
inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. 
Am J Pathol 1999, 155 (6), 1985-92. 
63 
 
62. Asirvatham, A. J.; Schmidt, M.; Gao, B.; Chaudhary, J., Androgens regulate the 
immune/inflammatory response and cell survival pathways in rat ventral prostate 
epithelial cells. Endocrinology 2006, 147 (1), 257-71. 
63. De Marzo, A. M.; Meeker, A. K.; Zha, S.; Luo, J.; Nakayama, M.; Platz, E. A.; 
Isaacs, W. B.; Nelson, W. G., Human prostate cancer precursors and 
pathobiology. Urology 2003, 62 (5, Supplement 1), 55-62. 
64. Biswas, S. K.; Mantovani, A., Orchestration of metabolism by macrophages. Cell 
Metab 2012, 15 (4), 432-7. 
65. Wilson, W. R.; Hay, M. P., Targeting hypoxia in cancer therapy. Nat Rev Cancer 
2011, 11 (6), 393-410. 
66. Mogensen, T. H., Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clin Microbiol Rev 2009, 22 (2), 240-73, Table of Contents. 
67. Liang, S. L.; Quirk, D.; Zhou, A., RNase L: its biological roles and regulation. 
IUBMB Life 2006, 58 (9), 508-14. 
68. Sadler, A. J.; Williams, B. R., Interferon-inducible antiviral effectors. Nat Rev 
Immunol 2008, 8 (7), 559-68. 
69. Vilcek, J., Novel interferons. Nat Immunol 2003, 4 (1), 8-9. 
70. Loza, M. J.; Perussia, B., Differential regulation of NK cell proliferation by type I and 
type II IFN. Int Immunol 2004, 16 (1), 23-32. 
71. Hardy, M. P.; Owczarek, C. M.; Jermiin, L. S.; Ejdeback, M.; Hertzog, P. J., 
Characterization of the type I interferon locus and identification of novel genes. 
Genomics 2004, 84 (2), 331-45. 
72. Sciarra, A.; Di Silverio, F.; Salciccia, S.; Autran Gomez, A. M.; Gentilucci, A.; 
Gentile, V., Inflammation and chronic prostatic diseases: evidence for a link? Eur 
Urol 2007, 52 (4), 964-72. 
73. De Marzo, A. M.; Meeker, A. K.; Zha, S.; Luo, J.; Nakayama, M.; Platz, E. A.; 
Isaacs, W. B.; Nelson, W. G., Human prostate cancer precursors and 
pathobiology. Urology 2003, 62 (5 Suppl 1), 55-62. 
74. De Marzo, A. M.; Platz, E. A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C. G.; 
Nakai, Y.; Isaacs, W. B.; Nelson, W. G., Inflammation in prostate carcinogenesis. 
Nat Rev Cancer 2007, 7 (4), 256-69. 
75. Karakiewicz, P. I.; Benayoun, S.; Begin, L. R.; Duclos, A.; Valiquette, L.; 
McCormack, M.; Benard, F.; Saad, F.; Perrotte, P., Chronic inflammation is 
negatively associated with prostate cancer and high-grade prostatic intraepithelial 
neoplasia on needle biopsy. Int J Clin Pract 2007, 61 (3), 425-30. 
64 
 
76. Goldstraw, M. A.; Besrani, D.; Amoroso, P.; Kirby, R. S., Is obesity a risk factor for 
prostate cancer? BJU international 2007, 100 (4), 726-8. 
77. Zheng, S. L.; Liu, W.; Wiklund, F.; Dimitrov, L.; Balter, K.; Sun, J.; Adami, H. O.; 
Johansson, J. E.; Sun, J.; Chang, B.; Loza, M.; Turner, A. R.; Bleecker, E. R.; 
Meyers, D. A.; Carpten, J. D.; Duggan, D.; Isaacs, W. B.; Xu, J.; Gronberg, H., A 
comprehensive association study for genes in inflammation pathway provides 
support for their roles in prostate cancer risk in the CAPS study. Prostate 2006, 
66 (14), 1556-64. 
78. Palapattu, G. S.; Sutcliffe, S.; Bastian, P. J.; Platz, E. A.; De Marzo, A. M.; Isaacs, W. 
B.; Nelson, W. G., Prostate carcinogenesis and inflammation: emerging insights. 
Carcinogenesis 2005, 26 (7), 1170-81. 
79. Sugar, L. M., Inflammation and prostate cancer. Can J Urol 2006, 13 Suppl 1, 46-7. 
80. Urisman, A.; Molinaro, R. J.; Fischer, N.; Plummer, S. J.; Casey, G.; Klein, E. A.; 
Malathi, K.; Magi-Galluzzi, C.; Tubbs, R. R.; Ganem, D.; Silverman, R. H.; 
Derisi, J. L., Identification of a Novel Gammaretrovirus in Prostate Tumors of 
Patients Homozygous for R462Q RNASEL Variant. PLoS Pathog 2006, 2 (3), 
e25. 
81. Helpap, B.; Bonkhoff, H.; Cockett, A.; Montironi, R.; Troncoso, P.; Waters, D.; 
Bostwick, D., Relationship between atypical adenomatous hyperplasia (AAH), 
prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma. 
Pathologica 1997, 89 (3), 288-300. 
82. Sanlioglu, A. D.; Koksal, I. T.; Ciftcioglu, A.; Baykara, M.; Luleci, G.; Sanlioglu, S., 
Differential expression of TRAIL and its receptors in benign and malignant 
prostate tissues. J Urol 2007, 177 (1), 359-64. 
83. Fiorucci, G.; Vannucchi, S.; Chiantore, M. V.; Percario, Z. A.; Affabris, E.; Romeo, 
G., TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal 
transducer with cancer therapeutic potential. Curr Pharm Des 2005, 11 (7), 933-
44. 
84. Andersen, J. B.; Li, X. L.; Judge, C. S.; Zhou, A.; Jha, B. K.; Shelby, S.; Zhou, L.; 
Silverman, R. H.; Hassel, B. A., Role of 2-5A-dependent RNase-L in senescence 
and longevity. Oncogene 2007, 26 (21), 3081-8. 
85. Dong, B.; Silverman, R. H., A bipartite model of 2-5A-dependent RNase L. J Biol 
Chem 1997, 272 (35), 22236-42. 
86. Kjaer, K. H.; Pahus, J.; Hansen, M. F.; Poulsen, J. B.; Christensen, E. I.; Justesen, J.; 
Martensen, P. M., Mitochondrial localization of the OAS1 p46 isoform associated 
with a common single nucleotide polymorphism. BMC Cell Biol 2014, 15, 33. 
65 
 
87. Li, X. L.; Blackford, J. A.; Judge, C. S.; Liu, M.; Xiao, W.; Kalvakolanu, D. V.; 
Hassel, B. A., RNase-L-dependent destabilization of interferon-induced mRNAs. 
A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 
2000, 275 (12), 8880-8. 
88. Silverman, R. H., Implications for RNase L in prostate cancer biology. Biochemistry 
2003, 42 (7), 1805-12. 
89. Wiklund, F.; Jonsson, B. A.; Brookes, A. J.; Stromqvist, L.; Adolfsson, J.; 
Emanuelsson, M.; Adami, H. O.; Augustsson-Balter, K.; Gronberg, H., Genetic 
analysis of the RNASEL gene in hereditary, familial, and sporadic prostate 
cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research 2004, 10 (21), 7150-6. 
90. Xiang, Y.; Wang, Z.; Murakami, J.; Plummer, S.; Klein, E. A.; Carpten, J. D.; Trent, 
J. M.; Isaacs, W. B.; Casey, G.; Silverman, R. H., Effects of RNase L mutations 
associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. 
Cancer Res 2003, 63 (20), 6795-801. 
91. Yakub, I.; Lillibridge, K. M.; Moran, A.; Gonzalez, O. Y.; Belmont, J.; Gibbs, R. A.; 
Tweardy, D. J., Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate 
synthetase and RNase L inpatients hospitalized with West Nile virus infection. J 
Infect Dis 2005, 192 (10), 1741-8. 
92. Carpten, J.; Nupponen, N.; Isaacs, S.; Sood, R.; Robbins, C.; Xu, J.; Faruque, M.; 
Moses, T.; Ewing, C.; Gillanders, E.; Hu, P.; Bujnovszky, P.; Makalowska, I.; 
Baffoe-Bonnie, A.; Faith, D.; Smith, J.; Stephan, D.; Wiley, K.; Brownstein, M.; 
Gildea, D.; Kelly, B.; Jenkins, R.; Hostetter, G.; Matikainen, M.; Schleutker, J.; 
Klinger, K.; Connors, T.; Xiang, Y.; Wang, Z.; De Marzo, A.; Papadopoulos, N.; 
Kallioniemi, O. P.; Burk, R.; Meyers, D.; Gronberg, H.; Meltzer, P.; Silverman, 
R.; Bailey-Wilson, J.; Walsh, P.; Isaacs, W.; Trent, J., Germline mutations in the 
ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002, 30 
(2), 181-4. 
93. Rios, J. J.; Perelygin, A. A.; Long, M. T.; Lear, T. L.; Zharkikh, A. A.; Brinton, M. 
A.; Adelson, D. L., Characterization of the equine 2'-5' oligoadenylate synthetase 
1 (OAS1) and ribonuclease L (RNASEL) innate immunity genes. BMC Genomics 
2007, 8, 313. 
94. Choi, U. Y.; Kang, J. S.; Hwang, Y. S.; Kim, Y. J., Oligoadenylate synthase-like 
(OASL) proteins: dual functions and associations with diseases. Exp Mol Med 
2015, 47, e144. 
95. Li, Y.; Banerjee, S.; Wang, Y.; Goldstein, S. A.; Dong, B.; Gaughan, C.; Silverman, 
R. H.; Weiss, S. R., Activation of RNase L is dependent on OAS3 expression 




96. Justesen, J.; Hartmann, R.; Kjeldgaard, N. O., Gene structure and function of the 2'-
5'-oligoadenylate synthetase family. Cell Mol Life Sci 2000, 57 (11), 1593-612. 
97. Donovan, J.; Dufner, M.; Korennykh, A., Structural basis for cytosolic double-
stranded RNA surveillance by human oligoadenylate synthetase 1. Proc Natl 
Acad Sci U S A 2013, 110 (5), 1652-7. 
98. Sarkar, S. N.; Pandey, M.; Sen, G. C., Assays for the interferon-induced enzyme 2',5' 
oligoadenylate synthetases. Methods Mol Med 2005, 116, 81-101. 
99. Hartmann, R.; Olsen, H. S.; Widder, S.; Jorgensen, R.; Justesen, J., p59OASL, a 2'-5' 
oligoadenylate synthetase like protein: a novel human gene related to the 2'-5' 
oligoadenylate synthetase family. Nucleic Acids Res 1998, 26 (18), 4121-8. 
100. Uhlen, M.; Bjorling, E.; Agaton, C.; Szigyarto, C. A.; Amini, B.; Andersen, E.; 
Andersson, A. C.; Angelidou, P.; Asplund, A.; Asplund, C.; Berglund, L.; 
Bergstrom, K.; Brumer, H.; Cerjan, D.; Ekstrom, M.; Elobeid, A.; Eriksson, C.; 
Fagerberg, L.; Falk, R.; Fall, J.; Forsberg, M.; Bjorklund, M. G.; Gumbel, K.; 
Halimi, A.; Hallin, I.; Hamsten, C.; Hansson, M.; Hedhammar, M.; Hercules, G.; 
Kampf, C.; Larsson, K.; Lindskog, M.; Lodewyckx, W.; Lund, J.; Lundeberg, J.; 
Magnusson, K.; Malm, E.; Nilsson, P.; Odling, J.; Oksvold, P.; Olsson, I.; Oster, 
E.; Ottosson, J.; Paavilainen, L.; Persson, A.; Rimini, R.; Rockberg, J.; Runeson, 
M.; Sivertsson, A.; Skollermo, A.; Steen, J.; Stenvall, M.; Sterky, F.; Stromberg, 
S.; Sundberg, M.; Tegel, H.; Tourle, S.; Wahlund, E.; Walden, A.; Wan, J.; 
Wernerus, H.; Westberg, J.; Wester, K.; Wrethagen, U.; Xu, L. L.; Hober, S.; 
Ponten, F., A human protein atlas for normal and cancer tissues based on antibody 
proteomics. Mol Cell Proteomics 2005, 4 (12), 1920-32. 
101. Domingo-Gil, E.; Esteban, M., Role of mitochondria in apoptosis induced by the 2-
5A system and mechanisms involved. Apoptosis 2006, 11 (5), 725-38. 
102. Ghosh, A.; Sarkar, S. N.; Rowe, T. M.; Sen, G. C., A specific isozyme of 2'-5' 
oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 
family. J Biol Chem 2001, 276 (27), 25447-55. 
103. Gomos, J. B.; Rowe, T. M.; Sarkar, S. N.; Kessler, S. P.; Sen, G. C., The 
proapoptotic 9-2 isozyme of 2-5 (A) synthetase cannot substitute for the sperm 
functions of the proapoptotic protein, Bax. J Interferon Cytokine Res 2002, 22 (2), 
199-206. 
104. Kulka, M.; Calvo, M. S.; Ngo, D. T.; Wales, S. Q.; Goswami, B. B., Activation of 
the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does 





105. Molinaro, R. J.; Jha, B. K.; Malathi, K.; Varambally, S.; Chinnaiyan, A. M.; 
Silverman, R. H., Selection and cloning of poly(rC)-binding protein 2 and Raf 
kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from 
prostate cancer cells. Nucleic Acids Res 2006, 34 (22), 6684-95. 
106. Li, H.; Chen, W.; Zhou, Y.; Abidi, P.; Sharpe, O.; Robinson, W. H.; Kraemer, F. B.; 
Liu, J., Identification of mRNA binding proteins that regulate the stability of LDL 
receptor mRNA through AU-rich elements. J Lipid Res 2009, 50 (5), 820-31. 
107. Dutt, A.; Beroukhim, R., Single nucleotide polymorphism array analysis of cancer. 
Curr Opin Oncol 2007, 19 (1), 43-9. 
108. Mandal, S.; Abebe, F.; Chaudhary, J., 2'-5' oligoadenylate synthetase 1 
polymorphism is associated with prostate cancer. Cancer 2011, 117 (24), 5509-
5518. 
109. Peacock, E.; Whiteley, P., Perlegen sciences, inc. Pharmacogenomics 2005, 6 (4), 
439-42. 
110. Bhosle, S. M.; Hunt, A.; Chaudhary, J., A Modified Coupled Spectrophotometric 
Method to Detect 2-5 Oligoadenylate Synthetase Activity in Prostate Cell Lines. 
Biol Proced Online 2016, 18, 9. 
111. Tessier, M. C.; Qu, H. Q.; Frechette, R.; Bacot, F.; Grabs, R.; Taback, S. P.; 
Lawson, M. L.; Kirsch, S. E.; Hudson, T. J.; Polychronakos, C., Type 1 diabetes 
and the OAS gene cluster: association with splicing polymorphism or haplotype? 
J Med Genet 2006, 43 (2), 129-32. 
112. Li, H.; Reksten, T. R.; Ice, J. A.; Kelly, J. A.; Adrianto, I.; Rasmussen, A.; Wang, 
S.; He, B.; Grundahl, K. M.; Glenn, S. B.; Miceli-Richard, C.; Bowman, S.; 
Lester, S.; Eriksson, P.; Eloranta, M. L.; Brun, J. G.; Goransson, L. G.; Harboe, 
E.; Guthridge, J. M.; Kaufman, K. M.; Kvarnstrom, M.; Cunninghame Graham, 
D. S.; Patel, K.; Adler, A. J.; Farris, A. D.; Brennan, M. T.; Chodosh, J.; 
Gopalakrishnan, R.; Weisman, M. H.; Venuturupalli, S.; Wallace, D. J.; Hefner, 
K. S.; Houston, G. D.; Huang, A. J. W.; Hughes, P. J.; Lewis, D. M.; Radfar, L.; 
Vista, E. S.; Edgar, C. E.; Rohrer, M. D.; Stone, D. U.; Vyse, T. J.; Harley, J. B.; 
Gaffney, P. M.; James, J. A.; Turner, S.; Alevizos, I.; Anaya, J. M.; Rhodus, N. 
L.; Segal, B. M.; Montgomery, C. G.; Scofield, R. H.; Kovats, S.; Mariette, X.; 
Ronnblom, L.; Witte, T.; Rischmueller, M.; Wahren-Herlenius, M.; Omdal, R.; 
Jonsson, R.; Ng, W. F.; for, U. K. P. S. s. S. R.; Nordmark, G.; Lessard, C. J.; 
Sivils, K. L., Identification of a Sjogren's syndrome susceptibility locus at OAS1 
that influences isoform switching, protein expression, and responsiveness to type I 
interferons. PLoS Genet 2017, 13 (6), e1006820. 
113. Wu, C.; Chen, X.; Shu, J.; Lee, C. T., Whole-genome expression analyses of type 2 
diabetes in human skin reveal altered immune function and burden of infection. 
Oncotarget 2017, 8 (21), 34601-34609. 
68 
 
114. Winer, D. A.; Winer, S.; Shen, L.; Wadia, P. P.; Yantha, J.; Paltser, G.; Tsui, H.; 
Wu, P.; Davidson, M. G.; Alonso, M. N.; Leong, H. X.; Glassford, A.; Caimol, 
M.; Kenkel, J. A.; Tedder, T. F.; McLaughlin, T.; Miklos, D. B.; Dosch, H. M.; 
Engleman, E. G., B cells promote insulin resistance through modulation of T cells 
and production of pathogenic IgG antibodies. Nat Med 2011, 17 (5), 610-7. 
115. Fabre, O.; Salehzada, T.; Lambert, K.; Boo Seok, Y.; Zhou, A.; Mercier, J.; Bisbal, 
C., RNase L controls terminal adipocyte differentiation, lipids storage and insulin 
sensitivity via CHOP10 mRNA regulation. Cell Death Differ 2012, 19 (9), 1470-
81. 
116. Tsai, S.; Clemente-Casares, X.; Revelo, X. S.; Winer, S.; Winer, D. A., Are obesity-
related insulin resistance and type 2 diabetes autoimmune diseases? Diabetes 
2015, 64 (6), 1886-97. 
117. Bing, P. F.; Xia, W.; Wang, L.; Zhang, Y. H.; Lei, S. F.; Deng, F. Y., Common 
Marker Genes Identified from Various Sample Types for Systemic Lupus 
Erythematosus. PLoS One 2016, 11 (6), e0156234. 
118. Volkers, N., Do autoimmune diseases raise the risk of cancer? Journal of the 
National Cancer Institute 1999, 91 (23), 1992-3. 
119. Sun, L. M.; Lin, C. L.; Chung, C. J.; Liang, J. A.; Sung, F. C.; Kao, C. H., Increased 
breast cancer risk for patients with multiple sclerosis: a nationwide population-
based cohort study. Eur J Neurol 2014, 21 (2), 238-44. 
120. Ragonese, P.; Aridon, P.; Vazzoler, G.; Mazzola, M. A.; Lo Re, V.; Lo Re, M.; 
Realmuto, S.; Alessi, S.; D'Amelio, M.; Savettieri, G.; Salemi, G., Association 
between multiple sclerosis, cancer risk, and immunosuppressant treatment: a 
cohort study. BMC Neurol 2017, 17 (1), 155. 
121. Joseph, C. G.; Darrah, E.; Shah, A. A.; Skora, A. D.; Casciola-Rosen, L. A.; Wigley, 
F. M.; Boin, F.; Fava, A.; Thoburn, C.; Kinde, I.; Jiao, Y.; Papadopoulos, N.; 
Kinzler, K. W.; Vogelstein, B.; Rosen, A., Association of the autoimmune disease 
scleroderma with an immunologic response to cancer. Science 2014, 343 (6167), 
152-7. 
122. Li, C. Z.; Kato, N.; Chang, J. H.; Muroyama, R.; Shao, R. X.; Dharel, N.; 
Sermsathanasawadi, R.; Kawabe, T.; Omata, M., Polymorphism of OAS-1 
determines liver fibrosis progression in hepatitis C by reduced ability to inhibit 
viral replication. Liver Int 2009, 29 (9), 1413-21. 
123. Knapp, S.; Yee, L. J.; Frodsham, A. J.; Hennig, B. J.; Hellier, S.; Zhang, L.; Wright, 
M.; Chiaramonte, M.; Graves, M.; Thomas, H. C.; Hill, A. V.; Thursz, M. R., 
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus 
infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003, 4 (6), 411-9. 
69 
 
124. Kajaste-Rudnitski, A.; Mashimo, T.; Frenkiel, M. P.; Guenet, J. L.; Lucas, M.; 
Despres, P., The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West 
Nile virus replication inside infected cells. J Biol Chem 2006, 281 (8), 4624-37. 
125. Urosevic, N., Is flavivirus resistance interferon type I-independent? Immunol Cell 
Biol 2003, 81 (3), 224-9. 
126. Behera, A. K.; Kumar, M.; Lockey, R. F.; Mohapatra, S. S., 2'-5' Oligoadenylate 
synthetase plays a critical role in interferon-gamma inhibition of respiratory 
syncytial virus infection of human epithelial cells. J Biol Chem 2002, 277 (28), 
25601-8. 
127. Hamano, E.; Hijikata, M.; Itoyama, S.; Quy, T.; Phi, N. C.; Long, H. T.; Ha le, D.; 
Ban, V. V.; Matsushita, I.; Yanai, H.; Kirikae, F.; Kirikae, T.; Kuratsuji, T.; 
Sasazuki, T.; Keicho, N., Polymorphisms of interferon-inducible genes OAS-1 
and MxA associated with SARS in the Vietnamese population. Biochem Biophys 
Res Commun 2005, 329 (4), 1234-9. 
128. Cai, Y.; Chen, Q.; Zhou, W.; Chu, C.; Ji, W.; Ding, Y.; Xu, J.; Ji, Z.; You, H.; 
Wang, J., Association analysis of polymorphisms in OAS1 with susceptibility and 
severity of hand, foot and mouth disease. Int J Immunogenet 2014, 41 (5), 384-92. 
129. Picat, M. Q.; Pellegrin, I.; Bitard, J.; Wittkop, L.; Proust-Lima, C.; Liquet, B.; 
Moreau, J. F.; Bonnet, F.; Blanco, P.; Thiebaut, R.; Cohort, A. C. A., Integrative 
Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in 
Successfully Treated HIV Patients. PLoS One 2017, 12 (1), e0169164. 
130. Domagalski, K.; Pawlowska, M.; Zalesna, A.; Pilarczyk, M.; Rajewski, P.; Halota, 
W.; Tretyn, A., Impact of IL28B and OAS gene family polymorphisms on 
interferon treatment response in Caucasian children chronically infected with 
hepatitis B virus. World J Gastroenterol 2016, 22 (41), 9186-9195. 
131. Wang, S. S.; Gonzalez, P.; Yu, K.; Porras, C.; Li, Q.; Safaeian, M.; Rodriguez, A. 
C.; Sherman, M. E.; Bratti, C.; Schiffman, M.; Wacholder, S.; Burk, R. D.; 
Herrero, R.; Chanock, S. J.; Hildesheim, A., Common genetic variants and risk 
for HPV persistence and progression to cervical cancer. PLoS One 2010, 5 (1), 
e8667. 
132. Pascale, M.; Pracella, D.; Barbazza, R.; Marongiu, B.; Roggero, E.; Bonin, S.; 
Stanta, G., Is human papillomavirus associated with prostate cancer survival? Dis 
Markers 2013, 35 (6), 607-13. 
133. Kuusksalu, A.; Truve, E.; Aaspollu, A.; Kelve, M.; Scheffer, U.; Muller, W. E.; 
Schroder, H. C., Impairment of intracellular antiviral defense with age: age-
dependent changes in expression of interferon-induced and double-stranded RNA-
activated 2-5A synthetase in rat. Mech Ageing Dev 1995, 78 (2), 103-15. 
70 
 
134. Rysiecki, G.; Gewert, D. R.; Williams, B. R., Constitutive expression of a 2',5'-
oligoadenylate synthetase cDNA results in increased antiviral activity and growth 
suppression. J Interferon Res 1989, 9 (6), 649-57. 
135. Brown, S. G.; Knowell, A. E.; Hunt, A.; Patel, D.; Bhosle, S.; Chaudhary, J., 
Interferon inducible antiviral MxA is inversely associated with prostate cancer 
and regulates cell cycle, invasion and Docetaxel induced apoptosis. The Prostate 
2015, 75 (3), 266-279. 
136. Clarke, G. M.; Anderson, C. A.; Pettersson, F. H.; Cardon, L. R.; Morris, A. P.; 
Zondervan, K. T., Basic statistical analysis in genetic case-control studies. Nature 
protocols 2011, 6 (2), 121-133. 
137. Chen, Y.-H.; Kao, J.-T., Multinomial logistic regression approach to haplotype 
association analysis in population-based case-control studies. BMC Genetics 
2006, 7, 43-43. 
138. Kolonel, L. N.; Henderson, B. E.; Hankin, J. H.; Nomura, A. M.; Wilkens, L. R.; 
Pike, M. C.; Stram, D. O.; Monroe, K. R.; Earle, M. E.; Nagamine, F. S., A 
multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J 
Epidemiol 2000, 151 (4), 346-57. 
139. Haiman, C. A.; Patterson, N.; Freedman, M. L.; Myers, S. R.; Pike, M. C.; 
Waliszewska, A.; Neubauer, J.; Tandon, A.; Schirmer, C.; McDonald, G. J.; 
Greenway, S. C.; Stram, D. O.; Le Marchand, L.; Kolonel, L. N.; Frasco, M.; 
Wong, D.; Pooler, L. C.; Ardlie, K.; Oakley-Girvan, I.; Whittemore, A. S.; 
Cooney, K. A.; John, E. M.; Ingles, S. A.; Altshuler, D.; Henderson, B. E.; Reich, 
D., Multiple regions within 8q24 independently affect risk for prostate cancer. Nat 
Genet 2007, 39 (5), 638-44. 
140. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M. A.; Bender, D.; 
Maller, J.; Sklar, P.; de Bakker, P. I.; Daly, M. J.; Sham, P. C., PLINK: a tool set 
for whole-genome association and population-based linkage analyses. Am J Hum 
Genet 2007, 81 (3), 559-75. 
141. Freidlin, B.; Zheng, G.; Li, Z.; Gastwirth, J. L., Trend tests for case-control studies 
of genetic markers: power, sample size and robustness. Hum Hered 2002, 53 (3), 
146-52. 
142. Kent, W. J.; Sugnet, C. W.; Furey, T. S.; Roskin, K. M.; Pringle, T. H.; Zahler, A. 
M.; Haussler, D., The human genome browser at UCSC. Genome research 2002, 
12 (6), 996-1006. 
143. Raney, B. J.; Dreszer, T. R.; Barber, G. P.; Clawson, H.; Fujita, P. A.; Wang, T.; 
Nguyen, N.; Paten, B.; Zweig, A. S.; Karolchik, D.; Kent, W. J., Track data hubs 
enable visualization of user-defined genome-wide annotations on the UCSC 
Genome Browser. Bioinformatics 2014, 30 (7), 1003-5. 
71 
 
144. Turner, S.; Armstrong, L. L.; Bradford, Y.; Carlson, C. S.; Crawford, D. C.; 
Crenshaw, A. T.; de Andrade, M.; Doheny, K. F.; Haines, J. L.; Hayes, G.; Jarvik, 
G.; Jiang, L.; Kullo, I. J.; Li, R.; Ling, H.; Manolio, T. A.; Matsumoto, M.; 
McCarty, C. A.; McDavid, A. N.; Mirel, D. B.; Paschall, J. E.; Pugh, E. W.; 
Rasmussen, L. V.; Wilke, R. A.; Zuvich, R. L.; Ritchie, M. D., Quality control 
procedures for genome-wide association studies. Curr Protoc Hum Genet 2011, 
Chapter 1, Unit1 19. 
145. Anderson, C. A.; Pettersson, F. H.; Clarke, G. M.; Cardon, L. R.; Morris, A. P.; 
Zondervan, K. T., Data quality control in genetic case-control association studies. 
Nat Protoc 2010, 5 (9), 1564-73. 
146.  Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B. E.; Sumer, S. O.; Aksoy, B. A.; 
Jacobsen, A.; Byrne, C. J.; Heuer, M. L.; Larsson, E.; Antipin, Y.; Reva, B.; 
Goldberg, A. P.; Sander, C.; Schultz, N., The cBio Cancer Genomics Portal: An 
Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer 
Discovery 2012, 2 (5), 401-404. 
147. Gao, J.; Aksoy, B. A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S. O.; Sun, Y.; 
Jacobsen, A.; Sinha, R.; Larsson, E.; Cerami, E.; Sander, C.; Schultz, N., 
Integrative analysis of complex cancer genomics and clinical profiles using the 
cBioPortal. Science signaling 2013, 6 (269), pl1. 
148. Packer, B. R.; Yeager, M.; Burdett, L.; Welch, R.; Beerman, M.; Qi, L.; Sicotte, H.; 
Staats, B.; Acharya, M.; Crenshaw, A.; Eckert, A.; Puri, V.; Gerhard, D. S.; 
Chanock, S. J., SNP500Cancer: a public resource for sequence validation, assay 
development, and frequency analysis for genetic variation in candidate genes. 
Nucleic Acids Res 2006, 34 (Database issue), D617-21. 
149. Wilkening, S.; Chen, B.; Bermejo, J. L.; Canzian, F., Is there still a need for 
candidate gene approaches in the era of genome-wide association studies? 
Genomics 2009, 93 (5), 415-9. 
150. Kim, J.; Oh, B.; Lim, J. E.; Kim, M. K., No Interaction with Alcohol Consumption, 
but Independent Effect of C12orf51 (HECTD4) on Type 2 Diabetes Mellitus in 
Korean Adults Aged 40-69 Years: The KoGES_Ansan and Ansung Study. PLoS 
One 2016, 11 (2), e0149321. 
151. Cha, S.; Park, A. Y.; Kang, C., A Genome-Wide Association Study Uncovers a 
Genetic Locus Associated with Thoracic-to-Hip Ratio in Koreans. PLoS One 
2015, 10 (12), e0145220. 
152. Teo, Y. Y., Common statistical issues in genome-wide association studies: a review 
on power, data quality control, genotype calling and population structure. Curr 
Opin Lipidol 2008, 19 (2), 133-43. 
72 
 
153. Wang, X.; Li, J.; Duan, Y.; Wu, H.; Xu, Q.; Zhang, Y., Whole genome sequencing 
analysis of lung adenocarcinoma in Xuanwei, China. Thorac Cancer 2017, 8 (2), 
88-96. 
154. Caux-Moncoutier, V.; Pages-Berhouet, S.; Michaux, D.; Asselain, B.; Castera, L.; 
De Pauw, A.; Buecher, B.; Gauthier-Villars, M.; Stoppa-Lyonnet, D.; Houdayer, 
C., Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic 
imbalance study. Eur J Hum Genet 2009, 17 (11), 1471-80. 
155. Stanford, J. L.; Just, J. J.; Gibbs, M.; Wicklund, K. G.; Neal, C. L.; Blumenstein, B. 
A.; Ostrander, E. A., Polymorphic repeats in the androgen receptor gene: 
molecular markers of prostate cancer risk. Cancer Res 1997, 57 (6), 1194-8. 
156. Stranger, B. E.; Stahl, E. A.; Raj, T., Progress and promise of genome-wide 
association studies for human complex trait genetics. Genetics 2011, 187 (2), 367-
83. 
157. Michel, S.; Liang, L.; Depner, M.; Klopp, N.; Ruether, A.; Kumar, A.; Schedel, M.; 
Vogelberg, C.; von Mutius, E.; von Berg, A.; Bufe, A.; Rietschel, E.; Heinzmann, 
A.; Laub, O.; Simma, B.; Frischer, T.; Genuneit, J.; Gut, I. G.; Schreiber, S.; 
Lathrop, M.; Illig, T.; Kabesch, M., Unifying candidate gene and GWAS 
Approaches in Asthma. PLoS One 2010, 5 (11), e13894. 
158. Hong, E. P.; Park, J. W., Sample size and statistical power calculation in genetic 
association studies. Genomics Inform 2012, 10 (2), 117-22. 
